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Targeting Aβ has recently been the main objective in Alzheimer’s 
disease therapeutic approaches. Passive immunization trials have 
encountered undesirable side effects but the therapy remains a 
promising option. Aβ4-x has not been previously considered as a target 
for AD immunotherapy. Tg4-42 mouse model has been recently 
established and validated as an advantageous research tool in AD. 
The current work deals with Aβ4-42 and explores its potential as a 
target, while elucidating therapeutic mechanism and crystallizing the 
NT4X Fab in complex with Aβ4-19 aiming to further reveal the 
structural basis of antibody: target affinity. 
In the present work, the novel monoclonal antibody NT4X 
specifically reacts with N-truncated Aβ at position 4 of Aβ. It binds N-
truncated Aβ under native and denaturing conditions and rescues in 
vitro toxicity of Aβ4-42 and that of pyroglutamate AβpE3-42. The Fab 
fragment of the antibody was also able to prevent the in vitro toxicity 
caused by Aβ4-42 in rat primary cortical neuron cultures. 
Aβ4-42 intracerebroventricular injection into wildtype mice 
induced a behavioral deficit, shown as a reduction in alteration rate 
in a Y-Maze, which was prevented using the NT4X. The Fab fragment 
of the antibody, at a higher dosage, was also able to prevent the in 
vivo behavioral deficit in a replicate experiment.   
The Tg4-42 homozygous mouse model, expressed Aβ4-42 and 
allows for is intraneuronal accumulation. At 6 months of age, the 
model already exhibits 50% neuronal loss in the CA1 region of the 
hippocampus and severe reference memory deficits in a Morris water 
maze. Preventative passive immunotherapy with the NT4X antibody 
and its Fab fragment was able to mitigate neuron loss significantly 
and rescue spatial memory deficits as compared to an isotype control 
group. 
Crystallization of the NT4X Fab in complex with Aβ4-19 has been 




resolve the crystal structure of the complex are ongoing. Issues with 
antibody-target engagement in terms of affinity, species and 
conformation of Aβ bound may be dealt with before going to a clinical 
setting, with the help of information arising from the crystal structure 
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1.1.  Dementia 
 
The clinical syndrome referred to as “Dementia” encompasses a 
wide range of underlying pathologies. Most commonly these include 
Alzheimer’s disease (AD), Lewy body dementia, vascular dementia and 
frontotemporal dementia. The common grounds underlying the 
aforementioned diseases is a progressive deterioration in cognitive 
ability and capacity for independent living, brought on via a slow 
process of neurodegeneration (Sousa et al., 2009, 2010). Attention, 
problem solving, language, memory and visual-spatial are the most 
common areas affected by the resulting neurodegeneration (Lee, 
2011). In the initial stages of dementia, manifestations of the 
symptoms are very subtle and often go unnoticed.  
Accounting for around 60 – 80% of dementia cases, Alzheimer’s 
disease is the most common form of dementia (Alzheimer’s 
Association, 2012).   
 
1.2.  Alzheimer’s disease 
 
Senile dementia, before the term Alzheimer’s disease was coined 
at the turn of the previous century following the description of 
Auguste Deter’s case, was well known, dating back to the ancient 
Greek and Roman philosophers and physicians. However, the 
histological findings and concepts presented by early researchers of 
AD, most notably Dr. Alois Alzheimer, were a turning point for the 
understanding of dementia (Berchtold & Cotman, 1998).  Estimates in 
France, Sweden, the United States and the Netherlands, consider 
Alzheimer’s disease the most costly disease for society after the age of 
65. The epidemiology of AD is closely linked with the increase in 




1.3.  Epidemiology  
 
The World Health Organization (WHO) projected that in 2005, 
0.379% of people worldwide had dementia, and that the prevalence 
would increase to 0.441% in 2015 and to 0.556% in 2030. A more 
recent WHO study estimates that in 2010, 47.5 million people had 
dementia, 35 million people of whom had Alzheimer’s disease (WHO, 
2010, 2015). In line with the previous, another study estimates that 
by 2050, the prevalence of AD will quadruple, by which time 1 in 85 
persons worldwide will be living with the disease (Brookmeyer et al., 
2007).  
The death attributable to Alzheimer’s disease and other 
dementias, seems to be correlated to both yearly income (World Bank 
income categories) and living region (WHO region). Where the low-
income category contributes to 0.41% of deaths as compared to 2.84% 
for the high-income category. Correspondingly, the Eurozone 
contributes to 2.04% of AD and other dementias related deaths as 
compared to 0.1% for Africa, 1.47 for the Americas and 0.42% for 
Eastern Mediterranean countries (WHO, 2006).  
 
1.4.  Risk Factors  
 
1.4.1.  Health 
 
Data from cross-sectional and longitudinal studies relating 
health risk factors to the risk of developing Alzheimer’s disease have 
mostly remained inconsistent.  
Hypertension has been suggested to increase the risk of AD 
through protein extravasation into brain tissue, caused by a decrease 
of the vascular integrity of the blood-brain barrier (BBB) (Kalaria, 
2010). Likewise, Types 2 diabetes, in observational studies, has been 
linked to almost doubling the risk of AD (Leibson et al., 1997; 






On the other hand, a lower risk of AD has been associated with 
case-control studies examining smoking (Ferini-Strambi et al., 1990; 
Tyas, 1996). Other health risk factors studied have been 
cerebrovascular disease (Weishaupt, 2003), body weight (Gustafson et 
al., 2009; Razay, 2005), plasma lipid levels (Kuo et al., 1998; 
Michikawa, 2003; Muckle & Roy, 1985) and traumatic brain injury 
(Mayeux et al., 1995; Rasmusson et al., 2009).  
 
1.4.2.  Environmental  
 
Some studies have examined the influence of toxic chemical 
exposures on the risk of dementia, Alzheimer’s disease and eventually, 
cognitive decline.  
Cognitive function including, verbal memory/learning, language, 
visual memory and more importantly visual spatial/motor functions, 
have been recently shown do be adversely affected by low-level 
additive exposure to lead outside of the work setting (Shih et al., 
2006).  
The potential role of aluminum in Alzheimer’s disease has been 
controversial since 1965. The relevance of a recent laboratory 
observation to actual real-life conditions has yet to be established 
since the prediction of aluminum absorption is not mainly 
extrapolated from the quantity of aluminum ingested. The study had 
found that a nano-molar amount of aluminum was able to induce 
gene expression, which promotes inflammation and cell death, similar 
to observed in AD. The study however, was conducted ex vivo on 
human neural cells (EFSA, 2008; Lukiw et al., 2005).  
Moreover, evidence has begun to develop regarding studies 
implicating pesticides, polychlorinated biphenyls (PCBs) and 






1.4.3.  Genetic factors 
 
Alzheimer’s disease may be classified into early onset AD 
(EOAD, onset <65 years), and late-onset AD (LOAD, onset ≥65 years) 
that accounts for more than 95% of cases. Less than 1% of AD cases 
are those of EOAD, with the majority of cases belonging to the 
category of LOAD (Blennow et al., 2006).  
While clinically indistinguishable from LOAD, EOAD is generally 
associated with a more rapid rate of progression and a Mendelian 
pattern of inheritance. 
 
1.4.3.1.  Early onset Alzheimer’s disease  
 
The Amyloid precursor protein (APP) as the name entails, is 
involved in the generation of amyloid beta (Aβ). Mutations in 
presenilin 1 and 2 (PS-1, PS-2) proteins results in an increase in 
production of full-length Aβ1-40/42. They have been firmly implicated in 
the pathology of EOAD through mutations in the gene encoding their 
proteins. Considered diagnostic biomarkers of EOAD, these mutations 
exhibit autosomal dominant inheritance and eventually lead with 
certainty to Aβ aggregation and an early onset of the disease (Reitz & 
Mayeux, 2014; Waring & Rosenberg, 2008). 
 
1.4.3.2.  Late onset Alzheimer’s disease  
 
Apolipoprotein E (APOE) is a lipid-binding protein and is 
expressed in humans as three common isoforms coded for by three 
alleles, APOEɛ2, ɛ3, and ɛ4. Located on chromosome 19q13, the 
APOEɛ4 allele is the only clearly recognized susceptibility gene in 
Alzheimer’s disease. While inhering a single copy of the APOEɛ4 allele 
increases the risk of developing AD by 2-3 fold, and lowering the age 
of onset by 6-7 years, it does not guarantee it. Having two copies of 
the APOEɛ4 allele is associated with an even higher risk of more than 
5 fold increase (Corder et al., 1993; Gomez-Isla et al., 1996b; Kuusisto 




1.4.4.  Genome wide association studies 
 
More recent genome-wide association studies (GWAS) have 
found 19 areas in genes that appear to affect the risk of developing 
AD. These genes include: CASS4, FERMT2, INPP5D, MS4A, PICALM, 
NME8, CD2AP, CELF1, HLA-DRB5, EPHA1, ZCWPW1, ABCA7, MEF2C, 
CLU, SORL1, BIN1, SlC24A4, PTK2B and CR1 (Lambert et al., 2013).   
 
1.5.  Neuropathological Hallmarks 
 
1.5.1.  Amyloid deposits  
 
Consisting of folded β-sheet structures, amyloid depositions are 
complex mosaic accumulations of protein. Referred to as amyloid 
plaques, they may be classified into either neuritic or diffuse plaques 
depending on size, shape and composition (Small, 1998; Yamaguchi et 
al., 1988).   
Neuritic plaques, as the name suggests, are extracellular 
depositions of fibrillar amyloid beta enclosed by dystrophic neurites. 
Dystrophic neurites are accumulations of enlarged axons 
and  dendrites amongst others enlarged lysosomes and numerous 
mitochondria. Ranging in size between 10 to 120 μm, in AD patients 
neuritic plaques contain many other proteins such as Tau, ubiquitin 
and the amyloid precursor protein (Norfray & Provenzale, 2004; 
Selkoe, 1989; Su et al., 1998).  
Diffuse plaques, on the other hand, are not enclosed by 
dystrophic neurites and may vary in size from 50 μm to a couple of 
hundred μm. They consists of amorphous and non-fibrillar Aβ 
depositions and were thought to represent the precursors of neuritic 
plaque generation (Dickson, 1997).  
Cerebral amyloid angiopathy (CAA) is another form of amyloid 
beta deposition, where Aβ accumulates inside the walls of blood 




1.5.2.  Neurofibrillary tangles 
 
Neurofibrillary tangles (NFT) are constituted of filament pairs, 
roughly 10 nm in width, wound into paired helical filaments (PHF) 
whose composition consists of hyperphosphorylated tau protein 
(Grundke-Iqbal et al., 1986; Kidd, 1963; Lee et al., 1991). Tau is 
primarily expressed in axons of the central nervous system. The 
hyperphosphorylation of tau leads to its dissociation from 
microtubules, where its primary function is their promotion and 
stabilization, thus aggregating into PHFs and destabilizing axons 
(Alonso et al., 2001; Hirokawa et al., 1996). NFTs are used for 
postmortem staging of AD, although they are acknowledged to be 
downstream amyloid pathology, yet they correlate better with clinical 
stages as compared to neuritic plaques (Braak & Braak, 1991).   
 
1.5.3.  Brain atrophy and neuron loss  
 
Being a neurodegenerative disease, another characteristic 
hallmark of AD pathology is brain atrophy. At the macroscopic level, 
this is exhibited via the enlargement of the ventricles, widening of the 
sulci and shrinkage of the gyri (Blennow et al., 2006). Marked by 
reduction in both volume and weight, magnetic resonance imaging 
(MRI) may be used to detect this alteration that is noticeable 
predominantly in the entorhinal cortex, amygdala and hippocampus 
(Bottino et al., 2002). Studies have shown that hippocampal volume 
and brain volume are correlated with neuron number, thus pointing 
towards neuron loss as the driving factor behind brain atrophy (Kril et 
al., 2004). 
The underlying cause driving the progression and severity of 
neuron loss in AD is a highly debated matter. While correlations have 
been made between neuron loss and NFTs (Gomez-Isla et al., 1997), 
more recently other groups have proposed that the key role is rather 
neurotoxicity induced by intraneuronal Aβ (Bayer & Wirths, 2010; 




using unbiased stereology have shown significant neuron loss in the 
entorhinal cortex (Gomez-Isla et al., 1996a), while later studies have 
also shown neuron loss in the superior temporal gyrus, amygdala, 
substantia nigra, supramarginal gyrus and region I of hippocampus 
proper (CA1) (Fig. 1.1) (Duyckaerts et al., 2009).   
 
 
Figure 1.1.  Brain atrophy in Alzheimer’s disease. Progressive brain 
atrophy in AD as compared to a preclinical stage. (Image modified from the 
National Institute of Health, Open Access source).  
 
 
1.6.  The Amyloid Precursor Protein  
 
The gene for the amyloid precursor protein (APP), in humans, is 
located on chromosome 21 (Yoshikai et al., 1990). It encodes an 
integral membrane protein whose primary function is yet unknown, 
yet has been proposed to be involved in iron export (Duce et al., 2010), 
neural plasticity (Turner et al., 2003)  and synapse formation  (Priller 
et al., 2006). As a precursor molecule, its subsequent pathological 
cleavage results in the generation of beta amyloid, a key player in 
Alzheimer’s disease.   
 
1.6.1.  Amyloidogenic and non-amyloidogenic processing 
 
In the normal physiological “non-amyloidogenic” pathway, α-
secretases that are membrane-bound and predominantly active at the 
cell surface (Sisodia, 1992), cleave APP around the middle region of 
the Aβ sequence (between amino acids 16 and 17, both Leucine). This 
leads to the release of the soluble sAPPα fragment into the 




Thereafter, γ-secretase cleaves the remaining C-terminal fragment 
(C83), thus producing the P3 fragment, which in contrast to Aβ is 
rapidly degraded, simultaneously producing the APP intracellular 
domain (AICD) that is thought to be a transcriptional regulator (Haass 
et al., 1993; Hartmann, 1999).   
However, in the pathological “amyloidogenic” pathway, APP is 
rather cleaved upstream of the α-secretase cleavage site by β-
secretase. This consequently releases a soluble N-terminal fragment 
(sAPPβ) and a longer C-terminal 99-residue fragment (C99), which 
remains membrane associated. γ-secretase then proceeds to cleave 
C99 at various sites within the transmembrane domain, generating Aβ 
peptides ranging from 37 to 43 amino acids in length. This also 
results in the production of the AICD fragment (Citron et al., 1995; 
De-Paula et al., 2012) (Fig. 1.2).   
It is of worth to note that the main constituent of amyloid 
plaques is Aβ containing 42 amino acids, while under normal 
biological conditions mainly Aβ containing 40 amino acids is 
generated and represents the major portion of the total Aβ (Zhang et 





 Figure 1.2.  APP processing and imbalance in age-related 
neurodegeneration. The amyloid precursor protein is processed either by an 
amyloidogenic pathway (left) or a canonical pathway (right). (Left) Beta 
secretase (BACE) cleaves APP resulting in increased amounts of ABP 
Carboxy-terminal fragment (CTFβ) and Aβ peptide (light blue) being secreted 
outside the cell.  The increased extracellular accumulation of toxic Aβ 
species, particularly Aβ42, results in the formation of Aβ oligomers. (Right) 
Normally, most APP is cleaved by the α-secretase, secreting sAPPα. CTFα is 
endocytosed and then processed by γ-secretase, resulting in formation of the 
p3 peptide, which is secreted, and releasing the AICD into the cytosol. BACE 
processing of APP does occur to generate Aβ (blue), but these are degraded 
and cleared. While few small plaques may accumulate with aging, they are 
much smaller and fewer in number than those associated with disease 







1.7.  Amyloid Beta 
 
As previously mentioned, amyloid beta (Aβ) is generated by the 
sequential cleavage of beta and gamma secretase resulting in the 
production of peptides varying in length. Apart from so called “full 
length” Aβ consisting of Aβ1-40 and Aβ1-42 several truncated versions 
have been reported such as C-truncated Aβ1-17, Aβ1-38 and Aβ1-39 
(Portelius et al., 2012; Wiltfang et al., 2002). New data has even 
described peptides similar to Aβ, which span amino acids 663-711, 
before the beta and gamma secretase cleavage sites (Kaneko et al., 
2014). Different Aβ isoforms, whether C- or N-truncated, possess a 
carrying degree of aggregation, stability and structure and neurotoxic 
activity (Bouter et al., 2013; Jarrett et al., 1993; Pike et al., 1995; 
Wirths et al., 2010). Of particular interest lately in AD therapy have 
been N-truncated Aβ peptides.   
 
1.7.1.  N-truncated amyloid beta 
 
The enzymatic activities that lead to N-terminal truncations are 
not fully understood. In some cases the question arises if the 
truncation has occurred after Aβ1-42 release or if it is an independent 
event. Meprin-β has recently been proposed to be responsible for 
generation of Aβ2-x peptides through cleavage of APP (Bien et al., 
2012). Neprilysin (NEP) cleaves between Arg-2 and Glu-3 or between 
Glu-3 and Phe-4, to generate N-truncated Aβ peptides (Howell et al., 
1995; Leissring et al., 2003). Furthermore, β-secretase, the enzyme 
responsible for the generation of Aβ1–x peptides, can also generate 
Aβ11–x peptides, through between Tyr-10 and Glu-11 (Vassar et al., 
1999). An overview of further proteases thought to be involved in N-






Figure 1.3.  Cleavage sites of enzymes potentially involved in 
generation of N-truncated Aβ peptides. Sequence of the first 17 amino 
acids of the N-terminus of human Aβ is shown in three-letter and one-letter-
code. Amino acids (AA) with charged polar side-chains are shown in red, AA 
with uncharged polar side-chains in green and hydrophobic non-polar AA in 
blue. (Figure adapted from (Bayer & Wirths, 2014), Open Access source)  
 
1.7.2.  N-truncated Aβ peptides in murine AD models  
 
The relative amount of N-truncated Aβ in human AD is much 
higher than levels reported in AD mouse model (Rüfenacht et al., 
2005). Nonetheless, several N-truncated forms of Aβ have been 
reported in murine models. The APP/PS1 KI model has measureable 
levels of Aβ4/5-x and AβpE3-x (Casas et al., 2004). Another study 
assessed the levels of AβpE3-x in the 5XFAD, Tg2576, APP/PS1ΔE9 and 
8 other models (Frost et al., 2013). Aβ5-42 has also recently been 
reported in both the 3xTg and 5XFAD models (Guzman et al., 2014).  
To further elucidate the toxicity of N-truncated Aβ peptides, 2 
models expressing only the AβpE3-x (TBA42) (Wittnam et al., 2012) and 
Aβ4-42 (Tg4-42) (Bouter et al., 2013), led to the intracellular 
accumulation of the respective peptides, accompanied by neuron loss 






1.7.3.  Amyloid hypothesis 
 
Initial explanations of the pathogenesis of Alzheimer’s disease 
arose from the amyloid cascade hypothesis that pointed the finger 
towards Aβ deposition as the causative factor in the etiology of AD. 
This thereby linked Aβ deposition to the eventual pathology in AD, 
claiming it lead to neuron and synapse loss, brain atrophy and 
eventually leading to dementia (Hardy & Higgins, 1992). Plaque 
formation caused by the accumulation of Aβ40 and Aβ42, caused by 
increased Aβ production or lack of its clearance, triggered the cascade 
(Pimplikar, 2009).   
Although the theory was heavily supported by a stream of 
evidence, mostly from familial AD cases studies (Bertram et al., 2010), 
murine AD models based on familial AD mutations (Duyckaerts et al., 
2008), down syndrome and triplication of the APP gene (Rumble et al., 
1989; Schupf & Sergievsky, 2002), the hypothesis had major flaws. 
The most important indication that the hypothesis was faulty came 
from evidence showing that cognitively normal individuals, showing no 
signs of dementia, had shown strong plaque deposition (Pimplikar, 
2009). Furthermore, both in human studies (Snowdon, 2003) and in 
AD mouse models (Walsh & Selkoe, 2007), plaque load does not 
correlate consistently with cognitive deficits/dementia.  
 
1.7.4.  Revised amyloid hypothesis 
 
In contrast to the classical amyloid hypothesis, a revised version 
dependent on the accumulation of intracellular Aβ peptides has been 
proposed. It proposes that intracellular Aβ could be secreted and re-
up taken from cells. Thus elevating levels of intracellular 
accumulation, is causative in downstream events such as neuronal 
and synaptosomal dysfunction leading to AD  (Wirths et al., 2004). 
This is supported by several observations, such as, in Down 
Syndrome intracellular Aβ is detectable at a young age and 




2001). Furthermore, classical AD mouse models, most of which carry 
a familial AD mutation and harbour strong plaque pathology, reflect 
human AD inflammatory pathology, but lack neuron loss (Wirths et 
al., 2004). To this end, recent mouse models such as the 5XFAD 
(Oakley et al., 2006), the APP/PS1KI (Casas et al., 2004) and the Tg4-
42 mouse model (Bouter et al., 2013) exhibit an early accumulation of 
intracellular Aβ and a correlation of behavioral deficits with neuron 
loss. This implies that Aβ oligomers, soluble intracellularly and 
extracellularly, play a pivotal role in the development and progression 
of early AD.   
 
1.8.  Treatment 
 
Current drugs designed to alleviate the clinical symptoms of AD 
mostly rely on neurotransmitter regulation. Since reduction in the 
activity of cholinergic neurons in AD has been extensively studied, 4 
drugs are acetylcholinesterase (Ach) inhibitors employed to slow down 
the rate of degradation of Ach (Birks & Harvey, 2006; Bullock et al., 
2005). These are galantamine, rivastigmine, donepezil and tacrine, 
which are marketed under different commercial names. The 5th drug 
is an N-methyl-D-aspartate receptor (NMDA) antagonist that blocks 
the glutamatergic system overstimulation by glutamate (Lipton, 2006). 
The benefit from their use is very limited and none of the drugs delays 
the progression of the disease or halts the clinical symptoms (Birks & 
Harvey, 2006). Observational studies suggest that combination 
treatment may increase the time before patients require nursing home 






1.8.1.  Targeting Aβ 
 
Targeting Aβ has recently been the main target in therapeutic 
approaches. Drugs have been aimed at either decrease the production 
of Aβ or enhance its clearance. The primary research focus has been 
on enzymes involved in Aβ production and their inhibition. β- or γ-
secretase inhibition has been attempted with limited success and side 
effects, as it has been difficult to develop drugs that penetrate the 
BBB, and precisely inhibit β- or γ-secretase. Unwanted side effects 
have been the cleavage of alternative substrates such as sodium 
channel subunits and Notch (Citron, 2010; De Strooper et al., 2010). 
Research focus has been on immunization approaches to reduce Aβ 
levels and enhance clearance (Lannfelt et al., 2014).   
 
1.8.2.  Active immunization 
 
Initial pre-clinical trials in active immunization were a 
breakthrough, using PDAPP transgenic mice, immunization with 
preparations of full length Aβ42 resulted in the clearance of amyloid 
plaques (Schenk et al., 1999). Other studies using different mouse 
models were similar in results and even lead to the amelioration of 
behavioral symptoms in the mice (Dodart et al., 2002; Janus et al., 
2000). Given the previous results, clinical trials in humans were 
approved hurriedly. Using Aβ preparations in AD patients initially 
reported no adverse effects (Schenk, 2002). However, the clinical 
phase 2A trials were subsequently halted due to the development of 
symptoms of central nervous system inflammation, in some patients, 
and some deaths due to pulmonary embolism (Ferrer et al., 2004; 
Gilman et al., 2005; Nicoll et al., 2003). The field afterwards turned to 
passive immunization as a means to overcome the negative side 





1.8.3.  Passive immunization 
 
As with any form of therapy that is taken from the bench to 
bedside application, passive immunization offers both advantages and 
disadvantages. The major disadvantage of passive immunization lies 
in the fact that repeated infusions of antibody over the lifetime of a 
patient would be necessary to maintain a desired therapeutic effect. 
The therapy however, offers a precise delivery of target specific 
antibodies to patients and the opportunity to rapidly decrease 
antibody titer if side effect should develop (Lannfelt et al., 2014).   
The first evidence of success in passive immunotherapy in an 
AD mouse model was demonstrated by Bard and colleagues in 2000. 
Wherein the systemic administration of the N-terminus 3D6 
monoclonal antibody eventually resulted in a decreased plaque 
burden (Bard et al., 2000). The humanized version of 3D6, 
Bapineuzumab, proceeded in phase I, II and III clinical trials but 
terminated after phase III trials did not achieve significant clinical 
efficiency (Lannfelt et al., 2014). A recent version of the antibody, 
AAB-003, engineered to reduce risk of vasogenic edema and micro-
haemorrhage, is now in phase I study.   
Other humanized antibodies currently still in various stages of 
clinical trials are Crenezumab (Genentech), BAN2401 (Biogen), 
LY3002813 (Eli Lilly & Co), SAR228810 (Sanofi) and Solanezumab (Eli 
Lilly & Co) (Clinicaltrials.gov).  
Although passive immunization trials have encountered 
undesirable side effects, and their long-term cost to the healthcare 






1.9.  Crystallization  
  
Crystallization is, a feature of precipitation, wherein the process 
of formation of solid crystals is driven through precipitation from a 
solution or gas. The two major events of crystallization are nucleation 
and crystal growth. The clustering of solute molecules, dispersed in 
the solvent, is a nanometer scale event referred to as nucleation. 
Conditions such as temperature, supersaturation, pH and more, will 
determine whether a cluster the critical size in order to become a 
stable nucleus (Fig. 1.4). Supersaturation is the driving force of crystal 
growth, with either nucleation or growth being predominant thus 
affecting the different sizes and shapes of crystals obtained. 
Crystallization is complete once supersaturation is drained and the 
solid-liquid system reaches equilibrium.  
 
Figure 1.4. Adjustable parameters for crystallization include precipitant 
or additive concentration, pH and temperature. The four major 
crystallization methods are represented: (i) microbatch, (ii) vapor diffusion, 
(iii) dialysis and (iv) FID. Each involves a different route to reach the 
nucleation and metastable zones, assuming the adjustable parameter is 
precipitant concentration. The filled black circles represent the starting 
conditions. Two alternative starting points are shown for FID and dialysis 
because the undersaturated protein solution can contain either protein 
alone or protein mixed with a low concentration of the precipitating agents. 
The solubility is defined as the concentration of protein in the solute that is 
in equilibrium with crystals. The supersolubility curve is defined as the line 




separation or precipitation) occurs from those under which the 
crystallization solution remains clear if left undisturbed. Figure and legend 
taken from (Chayen & Saridakis, 2008), used with permission from Nature 
Publishing Group, license number 3770641097789).  
 
1.9.1.  X-ray crystallography  
 
Is an experimental technique that is used to determine the three 
dimensional structure of a substance (e.g. protein, RNA, DNA, small 
molecules). It exploits the fact that periodically arranged atoms in the 
substance crystal diffract X-rays. Based on the resulting diffraction 
patterns, the electron density can be reconstructed and the structural 
model describing position of every atom of the substance can be built.  
Macromolecular crystallography is a technique used to study 
biological molecules such as nucleic acids and proteins to a resolution 
higher than 5 Å. It allows for the elucidation of protein structure and 
function and may also demonstrate interaction between 2 or more 
proteins. The crystallographic analysis of antigen-antibody complexes 
has been demonstrated (Edmundson et al., 1996).  
  
1.9.2.  Crystallization of anti-amyloid beta antibodies 
 
Alzheimer’s disease researchers have come to believe that the 
success of Aβ antibodies, currently in clinical development, in terms of 
eventual success in therapeutic trials, may be correlated with the 
precise spatial details of how the antibodies engage their antigen. A 
growing collection of crystal structures are building a knowledge base, 
in hopes of improving therapeutic outcome and minimize collateral 
activity such as vasogenic edema.  Each of the clinical anti-Aβ 
antibodies targets specific parts of the notorious peptide, though some 
of the binding profiles overlap. Some of the published crystal 
structures include that of Bapineuzumab (Crespi et al., 2014; 
Feinberg et al., 2014b; Miles et al., 2013), Solanezumab (Crespi et al., 
2015), Ponezumab (La Porte et al., 2012) and Gantanerumab 




1.10.  Objectives 
 
Targeting Aβ has recently been the main objective in Alzheimer’s 
disease therapeutic approaches. Passive immunization trials have 
encountered undesirable side effects but the therapy remains a 
promising option. Amyloid beta 4-x has not been previously 
considered as a target for AD immunotherapy. 
 
The current work’s objectives are the following: 
 The characterization of a novel antibody (NT4X-167) which 
recognizes N-truncated amyloid beta 
 The large scale purification of the NT4X antibody and its 
respective Fab fragment 
 The characterization of NT4X binding specificity and sensitivity 
 The investigation of NT4X in vitro and in vivo rescue of amyloid 
beta  
 The validation of Tg4-42 as a valid AD model for therapeutic 
intervention 
 The passive immunization of Tg4-42 with NT4X and 
determination of the mechanism of target engagement 
 
  





2. Materials and Methods 
 
2.1.  Animals  
 
2.1.1.  General considerations 
 
Murine lines were maintained in the central animal facility of 
the University Medicine Göttingen under standard housing conditions. 
For behavioral analysis, mice were kept under constant 12 h/12 h 
dark/light conditions and supplied with food and water ad libitum.  
Animal experiments were approved by the local animal 
protection authorities (Niedersächisches landesamt für 
Verbraucherschutz und Lebensmittelsicherheit) under the approval 
number 14/1450. 
All experiments were conducted in accordance with the approved 
protocols. 
 
2.1.2.  Transgenic mice   
 
Tg4-42 mice express human Aβ4-42 fused to the murine 
thyrotropin releasing hormone (TRH) signal peptide under the control 
of the neuronal Thy-1 promoter on a C57Bl/6J genetic background 
(Bouter et al., 2013). 
For this study only homozygous Tg4-42 mice were used (Tg4-
42hom). 
 
2.2.  Animal Experiments 
 
2.2.1.  Passive immunization 
 
The potential therapeutic effects of NT4X-167 were studied 
using a passive immunization approach in Tg4-42hom. Passive 
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immunization was performed by intraperitoneal injections of the Aβ-
specific monoclonal antibody NT4X (against the N-terminus of Aβ4-x) 
or its Fab fragment and compared to control groups using antibody of 
the same immunoglobulin class as NT4X (IgG2b).   
Tg4-42hom mice were immunized by injections of the NT4X 
antibody, 10mg/kg body weight, diluted in sterile Phosphate buffered 
saline (PBS) (pH 7.4). Mice received weekly injections beginning at 3 
months of age. Each mouse received a total of 12 injections. Behavior 
testing started between the 10th and the 11th injection. Animals were 
sacrificed after the last injection. 
Control groups comprised of Tg4-42hom mice received 
intraperitoneal IgG2b antibody (10mg/kg body weight) diluted in PBS. 
Control mice were treated exactly the same as the NT4X group 
receiving 12 injection of the respective control solution starting at 3 
months of age. Furthermore, a non-treated Tg4-42hom group served as 
an additional control.  
 
2.2.2.  Morris water maze 
 
Spatial reference memory in Tg4-42hom mice was evaluated using 
a modified version of the Morris water maze (Morris, 1984).  
Briefly, mice learn to use visual spatial cues to locate a hidden 
platform in a circular pool filled with opaque water. The pool was 
divided into four virtual quadrants that were defined based on their 
spatial relationship to the platform: left, right, opposite and target 
quadrant, which contains the submerged goal platform.  
ANY-Maze video tracking software (Stoelting Co.,Wood Dale, 
USA) was used to record escape latency, swimming speed and 
quadrant preference. 
The experiment began with three days of cued training during 
which the submerged platform was made visible with a triangular flag 
that extended upwards. Both the location of the platform and the 
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position where mice were introduced into the pool changed between 
trials. Each mouse received four training trials per day. 
Forty-eight hours after the last day of cued training, mice 
performed five days of acquisition training. For this part of testing, the 
flag was removed from the submerged platform. Both distal cues, 
existing in the room, and proximal visual cues attached to the outside 
of the pool, were used as learning cues. The platform location 
remained stationary for each mouse throughout training. Each mouse 
again received four training trials per day. 
Twenty-four hours after the last acquisition trial, a probe test 
was performed to assess long-term spatial reference memory. The 
platform was removed from the pool, and mice were introduced into 
the water from a novel entry point. Mice were then allowed to swim 
freely for one minute while their swimming path was recorded.  
Mice were sacrificed 24-48 hours after the probe trial. 
 
2.2.3.  Intracerebroventricular injection of soluble Aβ 
 
12-week-old male C57BL/6J mice (Janvier, Le Genest-St-Isle, 
France) were intracerebroventricularly (icv) injected under 
anesthetization. Freshly prepared Aβ4-42 peptides (50 pmol in 1 µL; 
0.1M PBS (pH 7.4)) or freshly prepared 50 pmol Aβ4-42 in combination 
with the NT4X antibody [1 or 10 pmol respectively in 1 µL; 0.1M 
phosphate-buffered saline (pH 7.4)] was injected into the right 
ventricle, with stereotaxic coordinates from the bregma (AP –0.22, L –
1.0 and D 2.5 in mm). Vehicle (0.1M phosphate-buffered saline) or 
vehicle in combination with 1 or 10 pmol NT4X respectively were 
injected into the right ventricle as a control. ICV injections were made 
using a 10-µl Hamilton microsyringe fitted with a 26-gauge needle. 
Four days following ICV infusion of Aβ peptides, working memory was 
assessed using the Y-maze test (Experiments performed by SynAging, 
Nancy, France). 
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2.2.4.  Y-Maze task 
 
Immediate spatial working memory performance in icv injected 
12-week-old male C57BL/6J wildtype mice was assessed by recording 
spontaneous alternation behavior in a Y-maze as described previously 
(Miller et al., 2008; Youssef et al., 2008). The Y-maze task was carried 
out on day four after Aβ4-42 and NT4X application. The maze was 
made of opaque plexiglas and each arm was 40 cm long, 16 cm high, 
9 cm wide and positioned at equal angles. Mice were placed at the end 
of one arm and allowed to move freely through the maze during a 5 
min session. The series of arm entries were recorded visually and arm 
entry was considered to be completed when the hind paws of the 
mouse were completely placed in the arm. Alternation was defined as 
successive entries into the three arms on overlapping triplet sets. The 
percentage alternation was calculated as the ratio of actual (total 
alternations) to possible alternations (defined as the number of arm 
entries minus two), multiplied by 100 (Experiments performed by 
SynAging, Nancy, France). 
 
2.3.  Electrophoresis of Peptides  
 
2.3.1.  Abeta peptide preparation 
 
Stock solutions of synthetic peptides for blotting (1mg/ml in 10 
mM NaOH; PSL, Heidelberg) were prepared, sonicated for 5 min in 
water bath (Sonorex RK 100H, Bandelin electronic), snap frozen in 
liquid nitrogen and stored at −80°C.  
 
2.3.2.  Western blot of synthetic peptides  
 
For Western blot analysis under reducing conditions 7 μg 
peptide per well (mixed with an equal volume of sample buffer) were 
loaded on 4-12% Tris-Tricin VarioGels (Anamed) and run at a 
constant current of 120 V. After electrophoresis, the peptides were 
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transferred onto 0.45 μm nitrocellulose membranes for 30 minutes 
per membrane at constant 25 mA in a semi-dry transfer chamber. 
Free binding sites were blocked with 10 % (w/v) non-fat dry milk 
dissolved in Tris- buffered saline supplemented with Tween-20 (TBS-T) 
(50 mM Tris(hydroxymethyl)- aminomethane (Tris) pH 8.0 
supplemented with 0.05 % (v/v) Tween-20) for one hour at room 
temperature (RT).  
For detection, the primary antibodies IC16 (1 μg/ml), 1–57 (1 
μg/ml) and NT4X (1 μg/ml) were dissolved in TBS-T and incubated on 
a shaker over night at 4 °C. After three, 5 min, washing steps with 
TBS-T, the secondary rabbit-anti-mouse horseradish peroxidase 
(HRP)-conjugated antibody was diluted 10000-fold in TBS-T and 
incubated with the membrane for 2 hours at RT. Blots were developed 
using Luminata Crescendo Western HRP Substrate (Millipore) and 
exposed with the ODYSSEY Fc (LI-COR). 
 
2.4.  NT4X-167 Antibody  
 
The novel oligomeric Aβ specific antibody NT4X (IgG2b; official 
name of cell line Aβ4-40 NT4X-167; DSM ACC3162) was generated by 
immunizing three Balb/c mice with unconjugated Aβ4-40. After 
preparation of the lymph nodes they were fused with the myeloma cell 
line P3-X63-Ag8 for generation of the hybridoma cells. The hybridoma 
supernatants of mixed clones were screened by Ezyme-linked 
Immunosorbent Assay (ELISA) and immunohistochemistry and 
subcloned. The idea behind the generation of novel oligomeric 
antibodies was that in solution Aβ4-40 peptides are forming stable 
aggregates that can be used as an epitope for antibodies that 
specifically bind at the N- terminus of Aβ4-40. Therefore Aβ4-40 was 
used for immunizing mice and positive clones were screened in four 
steps. (Antonios et al., 2013).  
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2.4.1.  NT4X hybridoma cell culture 
 
The NT4X hybridoma cell line was cultured in a serum-free media 
for hybridoma culture ISF-1 (Biochrom) and maintained in fed 
batch/continuous perfusion mode at 25% Oxygen, 5% CO2 and 37°C 
in a 3L glass vessel bioreactor (Applikon) controlled using ADI 1030 
(Applikon). The cell-culture supernatants were harvested by 
centrifugation at 500 g and the antibody containing media was 
collected. 
 
2.4.2.  NT4X purification 
 
Media was further centrifuged at 10,000 g for 30 min prior to 
Protein A affinity chromatography and pH was stabilized by addition 
of 20% (v/v) of PBS buffer. Media was loaded at 5 ml/min onto 
HiTrap™ Protein A HP (GE Healthcare) connected to an AKTAxpress 
(GE Healtcare). Further column washing and elution was done 
according to Protein A column manufacturer instructions. The eluted 
sample was further purified by size-exclusion chromatography using a 
HiLoad 26/60 Superdex 200 pg run in PBS on an AKTAxpress (GE 
Healthcare). 
 
2.4.3.  NT4X Fab generation and purification 
 
Fab fragments were produced utilizing papain digestion of the 
intact NT4X monoclonal antibody.  Papain agarose (Sigma) was pre-
activated, shaking at 1400 rpm, with 10 mM cysteine (Sigma) in PBS 
for 30 min at room temperature. Previously purified NT4X antibody (in 
PBS) was incubated for 4 hours at 37°C with pre-activated papain 
agarose (1 U agarose/5 mg antibody). Papain agarose was 
subsequently removed by filtration through a 0.45 µm filter. Filtrate 
was then dialyzed into Buffer A (20 mM Sodium Citrate, 20 mM NaCl, 
pH= 5.5) and afterwards loaded onto a MonoS 10/100 GL (GE 
Healthcare). Column was eluted using 30 column volumes, reaching a 
Ch2. Materials & Methods 
25 
 
10% gradient of Buffer B (20 mM Sodium Citrate, 1 M NaCl, pH= 5.5). 
Column eluate was immediately neutralized using Buffer C (1 M Tris, 
pH= 9.0).  
Fab Eluate was further purified and buffer exchanged by size-
exclusion chromatography using a HiLoad 26/60 Superdex 75 pg run 
in PBS or Tris 50 mM buffer on an AKTAxpress (GE Healthcare). 
 
2.4.4.  Antibody storage 
 
Both full length antibody and Fab fragment were concentrated to 
2 mg/ml with a 10 kDa molecular weight cut-off (MWCO) centrifugal 
concentrator (Amicon Ultra, Millipore), snap frozen in liquid nitrogen 
and stored at -80°C until further use. 
 
2.5.  In vitro neuroprotection assays 
 
2.5.1.  Full-length NT4X antibody neuroprotection assay 
 
Neurons were prepared from the cortex of 18 day old embryonic 
CD rat brains using a papain digestion kit (Worthington, Biochemical 
Corporation). Cells were plated at 3 × 105 cells/ml in 96 well Cell Coat, 
Poly-D-Lysine coated plates (Greiner) in Neurobasal media with 
Pen/Strep, L-glutamine and B27 supplement with antioxidants 
(Gibco, ThermoFisher). The plates were incubated in a humidified 
incubator at 37oC, 5% CO2 for two days prior to adding the antibodies 
and amyloid peptides. Media was removed from the plates and fresh 
Neurobasal media containing B27 supplement without antioxidants 
(Invitrogen) added to perform the assay. Purified antibody stocks 
(mouse NT4X IgG2b and an isotype control antibody) were diluted in 
sterile PBS (Ca/Mg free) and 10 µl added to a total volume of 100 µl 
per well to give a series of dilutions at the required concentration. 
HFIP treated and dried amyloid peptide aliquots (stored in a desiccator 
at −80 °C) were dissolved in 100 mM NaOH and further diluted in 
Neurobasal media without antioxidants to achieve final peptide 
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concentrations of 5 µM for both AβpE3-42 and Aβ1-42 and 10 µM for Aβ4-42 
peptide in the cell assay (Anaspec, Fremont, CA (Eurogentec) and 
California Peptide Research, San Francisco). The plates were 
incubated for seven days prior to LDH measurement with the 
CytoTox96 Non-Radioactive cytotoxicity assay kit (Promega). The LDH 
assay was performed on 50 µl/well culture supernatant in fresh 96 
well assay plates (Costar). The plates were read at 490 nm on a Tecan 
Safire II plate reader. The inhibition assay was repeated n = 2 to 3 for 
each peptide with the two antibodies detailed. (Experiment performed 
by MRC Technology, London, United Kingdom) 
 
2.5.2.  NT4X Fab fragment neuroprotection assay 
 
Cortical neurons from embryonic day 16–17 Wistar rat fetuses 
were prepared as previously described (Pillot et al., 1999). In brief, 
dissociated cortical cells were plated at 50,000 cells/well in 48-well 
plates precoated with 1.5 mg/mL polyornithine (Sigma). Cells were 
cultured in a chemically defined Dulbecco’s Modified Eagle’s/F12 
medium free of serum (Gibco) and supplemented with hormones, 
proteins and salts. Cultures were kept at 35°C in a humidified 5% 
CO2 atmosphere, and at 6–7 DIV, cortical population was determined 
to be at least 97% neurons by immunostaining as previously 
described (Youssef et al., 2008). At 6 DIV, the medium was removed 
and cortical neurons were incubated for 24 h with vehicle (cell culture 
medium) or Aβ peptides (dissolved in cell culture medium) at the 
indicated concentrations. Following a 24 h incubation of primary 
cortical neurons with Aβ peptides, cell viability was determined using 
a calcein-AM assay (Invitrogen, Molecular Probes).  
Briefly, cells were washed twice with PBS and incubated 
protected from light for 30 min at room temperature in the presence of 
2 µM calcein-AM solution prepared in PBS. Cells were then washed 
twice with PBS and incubated for 15 min at room temperature in PBS 
containing 1% Triton X-100 (v/v). The level of calcein fluorescence was 
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monitored by fluorescence emission at 530 nm after exciting at 485 
nm, using a Fluostar microplate reader (BMG-Lab technologies, 
France). (Experiment performed by SynAging, Nancy, France) 
 
2.6.  Tissue Experiments 
 
2.6.1.  Collection and preservation 
 
For all intended purposes, mice tissue was collected and 
preserved after transcardial perfusion of anaesthetised mice.  
First mouse is anaesthetised using 10 mL/kg intraperitonal 
injection of 1% Ketamin (Medistar, Ascheberg, Germany) and 0.1% 
Xylazin (Ecuphar, Belgium) in injectable grade water. Following deep 
anaesthesia, transcardial perfusion is carried out using ice-cold PBS 
buffer, followed by 4% paraformaldehyde (PFA) in PBS. Brain 
hemispheres were carefully divided at the midline. Left hemispheres 
were post fixed in 4% PFA overnight followed by 30% sucrose in PBS 
overnight. Following day, the tissue is frozen on dry ice and stored at -
80°C until further processing. 
Right brain hemispheres were post fixed in 4% buffered formalin 
(Roth, Karlsruhe, Germany) at 4°C before the tissue was embedded in 
paraffin by dehydration in a series of ethanol of 50%, 60%, 70%, 80%, 
90%, and 2x 100% ethanol followed by Xylol treatment.  Finally, 
tissue was immersed in liquid paraffin for 2 hours before being 
embedded in solid paraffin blocks.  
 
2.6.2.  Neuronal quantification  
 
2.6.2.1.  Cresyl violet staining  
 
For neuronal stereology, frozen left hemispheres brains were cut 
in 10 series of 30 μm coronal sections with collection of every 10th 
section throughout the brain and stored frozen at -80°C until further 
processing.  
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One series comprising every 10th section from each animal was 
carefully mounted in PBS onto super frost glass slides and left to dry 
overnight at room temperature. 
Sections were washed 2 x 10 min in 0.04 M Sodium acetate, 
0.1% acetic acid solution (Solution 1), delipidated 20 min in 0.025% 
Triton X-100; 75% ethanol, washed 2 x 10 min in solution 1 and 
stained for 2 x 8 min in 0.01% cresyl violet dissolved in solution 1.  
The sections were then washed 3 x 1 min in solution 1, 3 min in 
100% ethanol, 10 min in isopropanol, and 2 x 5 min in xylol before 
being embedded in Roti-Histokitt (Roth) mounting medium. 
 
2.6.2.2.  Unbiased stereology 
 
Stereological analysis was performed as previously described 
(Bouter et al., 2013). Briefly, mice were anaesthetized and 
transcardially perfused with 4% paraformaldehyde. Brains were 
carefully removed from the skull, dissected and post-fixed. The left 
brain hemispheres were cryoprotected in 30% sucrose, quickly frozen 
and cut frontally into entire series of 30 μm thick sections on a 
cryostat (Microm HM550, Germany). Every tenth section was 
systematically sampled, stained with cresyl violet and used for 
stereological analysis of the neuron number in the CA1. The 
hippocampal cell layer CA1 (Bregma -1.22 to -3.52 mm) was 
delineated on cresyl violet stained sections. Using a stereology 
workstation (Olympus BX51 with a motorized specimen stage for 
automatic sampling), StereoInvestigator 7 (MicroBrightField, Williston, 
USA) and a 100x oil lens (NA = 1.35), neuronal nuclei were sampled 
systematically using optical dissector probes, and the total number of 
neurons was subsequently estimated by the fractionator method using 
a 2 μm top guard zone.  
Age and sex-matched mice were analyzed for all groups. Samples 
were blinded to avoid biased counting.  
 




2.7.  Crystallization 
 
2.7.1.  General crystallography setup 
 
Crystallization of the Fab portion of the NT4X antibody or the Fab 
bound to respective Aβ peptides was carried out at 20 ºC using the 
sitting drop vapor diffusion method. Different commercial 
crystallization reagents were screened to identify initial conditions. 
Initial crystals were obtained by mixing 60 nl protein solution with 60 
nl reservoir solution in 96-well MRC plates using a Cartesian liquid 
dispensing robot with 8 channels. For grid screening with seeding, 
crystals were obtained by mixing 100 nl protein solution, 100 nl 
reservoir solution, and 20 nl seed stocks/dilutions in 96-well INTELLI-
PLATEs using the Gryphon liquid handling system (Art Robbins 
Instruments). For growing larger crystals, manual drops of 1 µl 
protein, 1 µl reservoir solution and 200 nl seed stock/dilution were set 
up in 24-well plates. Crystal growth was monitored by imaging with 
RockImager (Formulatrix, Bedford, United States).  
 
2.7.2.  Crystallization and diffraction data collection 
 
Fab-Aβ complex preparation was done as follows. Peptide 
corresponding to residues 4-19 of the human amyloid beta sequence 
(FRHDSGYEVHHQKLVF) was purchased from Peptide Specialty 
Laboratories (Germany) at 95% purity. Peptide was re-suspended in 
50 mM Tris, 150 mM NaCl (pH= 7.5) and added to Fab in a Fab:Aβ 
ratio of 1:5 and left on ice for 4 hours to allow for antibody antigen 
binding. Final Fab concentration used for successful crystallization 
trials was 5 mg/ml.  
Crystal seed stocks were prepared with Seed Bead™ kit and done 
according to manufacturer’s instructions (Hampton Research, United 
States). Seeding was attempted by the use of horse’s tail hair but was 
unsuccessful. Direct seeding resulted in diffraction quality crystals, 
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where seed stocks or dilutions were directly added to protein + 
reservoir combination.  
X-ray diffraction data were collected at beamline PXII of SLS 
(Paul Scherrer Institute, Villigen, Switzerland) and beamline 14.2 of 
BESSY II (HZB, Berlin, Germany). An example of data collection 
parameters (example) is summarized in Table 2.1 below.  
 
Table 2.1.   X-ray diffraction data collection parameters. 
Parameter Setting 
Detector distance (mm) 390 
Φ / ΔΦ (o) 360 / 0.5 
Exposure time (s) 0.3 
Beam intensity 0.2 
λ (Å) 1 










3.1.  Full-length NT4X Purification 
 
Initial NT4X antibody purification was attempted using 
Ammonium Sulfate precipitation (50-70% w/v). However, due to the 
use of serum-free culture media, antibody-containing hybridoma 
supernatant could be loaded onto a Protein A column (GE Healthcare) 
after pelleting cell debris through centrifugation. Elution with low pH 
solution resulted in antibody disengagement from column. Antibody 
buffer was subsequently exchanged into appropriate storage/usage 






















Figure 3.1.  NT4X antibody purification from hybridoma cell line DSM 
ACC3162 using immobilized protein A. Left peak, antibody purification 
from culture media using protein A. Right peak, antibody buffer exchange 
using HiPrep 26/10 desalting column (GE Healthcare).  
 
NT4X antibody purification was tracked at various stages of 
purification through sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE) gels stained either by coomassie or silver 
staining. Hybridoma media contained antibody and various other 
proteins that were required for hybridoma cell line maintenance. 
Following Protein A column, only full antibody and some antibody 
fragments were collected in eluate. Column flow-through (FW) still 
contained antibody and was re-loaded on protein A column (2-3 times) 
until no more antibody was detectable in FW (Fig 3.2). An antibody 






Figure 3.2.  Coomassie stained SDS-PAGE gel (non-reducing) tracking 
NT4X antibody purification. From left to right: Hybridoma Media collected 
post centrifugation, Antibody eluted from Protein A column, antibody buffer 
exchanged, column flow-through showing antibody remaining in media, and 
Protein A column wash (right). 
  
 To further purify the NT4X from smaller antibody fragments that 
eluted along with full-length antibody, the resulting eluate from the 
Protein A column was concentrated and injected into a HiLoad 26/60 
Superdex 200 pg size-exclusion column in PBS. Fractions from 
different peaks were analyzed. Peak 1 contained full-length antibody 







Figure 3.3.  Coomassie stained SDS-PAGE gel (non-reducing) tracking 
NT4X antibody purification following size-exclusion chromatography. 
Using HiLoad 16/600 Superdex 200 pg. Fractions from Peak 1 are 
represented on gel demonstrating a high purity antibody preparation. 
 
 In order to validate antibody presence in hybridoma media and 
throughout purification steps; a reducing PAGE-SDS gel was run and 
either stained by coomassie (Fig 3.4A) or transferred to a 
nitrocellulose membrane and probed using a mouse secondary 
antibody (Fig 3.4B). Coomassie gel revealed the presence of heavy and 
light chains (50 kDa and 25 kDa respectively) and probed membrane 








Figure 3.4.  Validation of antibody presence during purification process 
(A) Coomassie stained SDS-PAGE gel (reducing), verifying presence of both 
heavy-chain and light chain fragments of antibody and (B) Western blot of 
similar gel using a mouse secondary HRP conjugated antibody, revealed that 






3.2.  NT4X Fab Generation and Purification 
 
Antibody was incubated with papain for the duration of the 
reaction. Papain was initially not pre-activated. Reaction at room 
temperature (a) resulted in partial digestion of antibody while reaction 
at 37o C resulted in the creation of the fab fragment (at 50 kDa) within 
the time frame. Smaller digestion products at 15 kDa and 25 kDa 
were also noticeable. The constant region of the antibody (FC) was 
subsequently removed by binding digest on a Protein A column where 
the FC fragment would bind but the Fab would pass in the FW (Fig. 
3.5).  
 
Figure 3.5.  NT4X antibody digestion using papain (a) antibody incubated 
at room temperature for duration of digestion (b) antibody incubated in a 




Numerous purification strategies were tried for the purpose of 
further purifying the Fab fragment from smaller unwanted digestion 
products. Size exclusion chromatography was not successful in 
separating components. Ion exchange chromatography using a strong 
cation exchanger (Mono S prepacked with MonoBeads) was able to 
bind products resulting from papain digestion and successfully 
separated one component (peak 4) using a very shallow gradient. 
Peaks 1, 2, and 3 overlapped in elution profiles and were not fully 
separated, this was due to the fact that they eluted at 3.3 mS/cm, 
3.45 mS/cm and 3.6 mS/cm respectively (Fig 3.6).  
 
 
Figure 3.6. Mono S purification chromatogram showing 2 main eluted 






Fractions from Mono S purification were analysed using SDS-
PAGE and visualized using coomassie. Peak 1 contained two proteins 
(50 kDa), peak 2 early fractions contained same as peak 1 while 
fractions that eluted later contained 3 proteins (50 kDa, 25 kDa and 
15 kDa), peak 3 contained same proteins as late fractions from peak 2 
and finally peak 4 contained a double band of protein (15 kDa) (Fig 
3.7). As was apparent from the Mono S purification chromatogram, 
peaks 1, 2, and 3 were not properly separated while peak 4 was 




Figure 3.7.  Mono S purification fractions SDS-PAGE. Numbers represent 
respective peaks in Mono S purification chromatogram. 
 
A modified digestion protocol using pre-activated papain was 
eventually used and proved successful in reducing unwanted 
digestion products. Papain was incubated with cysteine for 30 
minutes in order to activate the enzyme. Buffer was then exchanged to 
one not containing cysteine for the duration of digestion. Digestion 
products were loaded unto protein A column several times to bind 
undigested full antibody and Fc fragments. After 3rd pass on protein A 
column, Fab fragment (50 kDa, flow-through 3 and 4) was obtained in 




either PBS or Tris buffer. Eluate from protein A column contained 
undigested (150 kDa), partially digested (100 kDa), and Fc fragment of 
antibody (Fig 3.8). 
 
 
Figure 3.8.  Modified antibody digestion protocol. Using pre-activated 
papain and subsequent purification with protein A column. Left to right. 
Papain digestion, FWs from successive loading on protein A column (FW 3 
and 4 contain pure Fab) and eluate from protein A column showing 








3.3.  Crystallization  
 
Intended workflow for the purification and crystallization the 
NT4X Fab fragment and the Fab bound to a respective amyloid beta 
peptide may be found below. As the previous parts have already 
described the purification part, this part will deal with the 




Figure 3.9.  Flowchart describing intended process of crystallization. 
The large scale purification has been described in previous section. 




Purification of the NT4X Fab 
fragment










3.3.1.  Initial screening 
 
Screening for crystallization conditions for the Fab fragment of 
the NT4X antibody was performed to expose the protein to a variety of 
agents in order to find “hits” that point to conditions that may result 
in crystallization. The most common way to adjust crystallization 
conditions is by varying the concentration of protein, type and 
concentration of precipitant, and pH or temperature. In the initial 
screening, conditions were tested out in various concentrations of the 
Fab in order to first ascertain the appropriate concentration while 
simultaneously screening precipitants and buffers.    
The primary objective of the screening process was to find 
conditions in which the Fab either formed crystals, crystalline 
precipitate or phase separation from the reservoir buffer used. 
Screening was done in 96 well format plates using the NeXtal tube 
suits (Qiagen) (Fig 10).  
Initial screening included the following suites:  
 




AmSO4 Anions Cations Classics
Classics II Classics Lite MbClass MbClass II





The vapor diffusion method was used where the protein solution 
was set up in a sitting drop that equilibrated against crystallizing 
agents at either higher or lower concentrations than in the drop. This 
provided a way to sample the crystallization parameter space, as the 
conditions vary continuously as equilibration proceeds. Screening was 
performed using 3 concentrations: 5, 13 and 20 mg/ml. Heavy 
precipitation was noticeable in both the 13 and 20 mg/ml (Fig 3.11b) 
screens while light precipitation was noticeable in the 5 mg/ml (Fig 
3.11a) screens. Moreover, screens which contained polyethylene glycol 
(PEG), of various molecular weights and concentrations, at 5 mg/ml 






Figure 3.11.  Different concentrations used in screening for 
crystallization conditions of the NT4X Fab fragment. Representative 
plates from Qiagen PEG screen. Images taken at time zero immediately after 





Crystals were first obtained in various conditions in which PEG 
was the main precipitant. Crystal growth was monitored and observed 
0-10 days after drops were set. Depending on the crystallization 
condition in the respective drops, crystals took between 1-3 days to 
appear. Crystals for the Fab grew in 25% PEG 3000 and 4000, 0.1 M 
Tris HCl reservoir solutions (Fig 3.12).  
 
 
Figure 3.12.  Representative images from initial crystals of Fab 
fragment obtained through screening (a) Crystals may be seen below the 
surface of the drop (b) several superimposed crystals, amorphous in shape.  
 
To verify that crystals obtained were not salt crystals, best 
crystals obtained from screening were fished from corresponding 
drops and soaked/washed in reservoir buffer before being loaded on 
an SDS-PAGE along with loading buffer (Fig 3.13). Lane (1) 
demonstrates protein band of crystal visualized using silver staining 
as compared to lane (2) which contained protein sample used to set 
up crystallization screens, both of which ran at around 50 kDa. This 
demonstrated that crystals grown were indeed formed by the Fab 








Figure 3.13.  Verification that crystals grown were consistent with Fab 
fragment where crystal from (b) was loaded on gel (a) and visualized using 
silver staining.   
 
3.3.2.  Fab + Aβ4-19 
 
In order to better study the structural basis for Aβ recognition of 
the NT4X antibody, the NT4X Fab was co-crystallized together with an 
N-truncated Aβ peptide. The Aβ4-19 peptide was used as the antibody 
has the highest affinity to the N-terminal part of Aβ starting at 
position 4. Initial crystals of the Fab bound to the Aβ4-19 peptide grew 
in similar conditions all containing PEG as precipitant.  Initial hits 
were in following reservoir solutions (Fab+Aβ4-19: 5.5 mg/mL): 
 25% PEG 2000 MME, 0.1 M  NaOAc trihydrate pH 4.6 (Fig 
3.14a) 
 25% PEG 3000, 0.1 M NaOAc trihydrate pH 4.6 (Fig 3.14b) 
 25% PEG 3350, 0.1 M NaOAc trihydrate pH 4.6 
 25% PEG 6000, 0.1 M NaOAc trihydrate pH 4.6 (Fig 3.14c) 






Figure 3.14. Crystals from initial hits of Fab+Aβ4-19 complex. Crystals 
grown in reservoir solution containing 0.1 M NaOAc trihydrate pH 4.6 buffer 
and (a) 25% PEG 2000 MME (b) 25% PEG 3000 (c) 25% PEG 6000. 
 
3.3.2.1.  Refinement 
 
Refinement grids were consequently designed around the 
conditions where initial hits were observed. Grids varied the 
concentration of PEG using used (between 20-30% in small 1% 
increments) and the pH of the NaOAc trihydrate buffer used (between 
pH 4 and 5, in 0.1 pH increments). Best crystals obtained were in 25% 
PEG 2000 MME and 24% PEG 8000, both in 0.1 M NaOAc trihydrate 
pH 4.6. Replicates of the conditions were then setup in both 96 and 
24 well formats. Best diffraction quality crystals obtained were from 
96 well plates. Crystals from PEG 2000 MME reservoirs took 3 days to 
appear and a total of 10 days to grow and diffracted up to 9 Ǻ (Fig 
3.15a). Crystals from PEG 8000 reservoirs took 2 days to appear and 





Figure 3.15.  First diffraction quality crystals from Fab+Aβ4-19 complex. 
Crystals grown in reservoir solution containing 0.1 M NaOAc trihydrate pH 
4.6 buffer and (a) 25% PEG 2000 MME, diffracted to 9 Ǻ (b) 24% PEG 8000, 
diffracted to 5 Ǻ. 
 
3.3.2.2.  Seeding 
 
Best crystals grown in PEG 8000 were used to prepare seed 
stock solutions. Seeding was performed in 96 well format and in 24 
well plates. Seeding was done using gradients of different PEGs (3000, 
6000, and 8000) and even using commercial PEG I and II screens 
from Qiagen. Best crystals resulting from seeding were from 23-24% 
PEG 3000, and were again used to prepare fresh seed stocks from 
which replicate plates of 23-24% PEG 3000, 0.1 M NaOAc trihydrate 
pH 4.6 were set in both 96 and 24 well format. Seeding was done in 
this sequential manner several times. Best diffraction quality crystals 
resulting from seeding, grew in 23.27% PEG 3000 in both 200 nl (Fig 
3.16a) drops and 2 µl drops (Fig 3.16b), both of which diffracted well. 
Crystals grown in 200 nl drops grew between 50-100 µm, while 





Figure 3.16.  Crystals from Fab+Aβ4-19 complex using seeding. Crystals 
grown in reservoir solution containing 0.1 M NaOAc trihydrate pH 4.6 buffer 
and 23.27% PEG 3000 (a) in 200 nl drops, 50-100 µm (b) in 2 µl drops, 200 
µm. 
 
3.3.3.  Crystal diffraction 
 
Several complete datasets from crystals diffraction were 
collected, the best of which was at 2.8 Ǻ (Fig 3.17) and collected from 
a crystal grown in 2 µl drops and cryoprotected using 30% glycerine in 
reservoir solution of 0.1 M NaOAc trihydrate pH 4.6 buffer and 
23.27% PEG 3000.  
 
Figure 3.17.  Crystal diffraction. Collected at 2.8 Ǻ from crystal grown in 





3.4.  Characterization of NT4X 
 
3.4.1.  Aβ binding properties of NT4X under reducing 
conditions 
 
Freshly dissolved Aβ peptides were subjected to SDS- PAGE to 
dissect the binding specificity of the three tested antibodies. Under 
denaturing conditions NT4X reacted with both N-terminally truncated 
AβpE3-X and Aβ4-X variants, but not with Aβ1-X. In addition to monomers 
and dimers, trimers and tetramers of AβpE3-42 and Aβ4–42 were 
recognized. AβpE3-40 and Aβ4–40 produced primarily monomers and 
dimers. Antibody 1–57 stained only AβpE3-40 and AβpE3-42, but no other 
bands as previously demonstrated. IC16 recognized the N-terminus of 
full-length Aβ1–40 and Aβ1–42, but not any of the N-truncated peptides 
(Fig 3.18).   
 
Figure 3.18. SDS-PAGE Western blot analysis of IC16, 1–57 and NT4X 
antibodies. Freshly dissolved synthetic Aβ variants were probed to a 
membrane. (a) IC16 detects Aβ1–40 and Aβ1–42 monomers and low molecular 
weight aggregates. (b) 1–57 recognizes AβpE3-40 and AβpE3-42 monomers, low 
molecular weight and larger aggregates of AβpE3-42. (c) NT4X recognizes 






3.4.2.  Sensitivity of NT4X to Aβ4-42   
 
In order to analyze the sensitivity of NT4X, a dilution series was 
performed with freshly dissolved synthetic Aβ4–42 and the staining was 
visualized using a Western blot under reducing conditions. NT4X 
detected monomers and dimers between 1 and 0.03 μg corresponding 
to a minimum of approximately 7 picomoles of Aβ4–42 (Fig 3.19).  
 
Figure 3.19. SDS-PAGE Western blot analysis of Aβ4-42 for sensitivity 
testing of NT4X using freshly dissolved peptides. NT4X detects monomers 
and dimers of Aβ4-42 up to 0.03 μg peptide. 
 
3.5.  NT4X and Fab Fragment in vitro Rescue of Aβ 
Toxicity 
 
In vitro assays were set up using primary rat cortical cultures to 
investigate the protective properties of the NT4X antibody against the 
various amyloid peptides. Concomitant with the binding properties of 
the antibody, NT4X rescues AβpE3-42 and Aβ4-42 oligomer induced 
toxicity but not of full-length Aβ1-42 induced toxicity (Fig 3.20).  






Figure 3.20. NT4X protection of AβpE3-42 and Aβ4-42 induced toxicity in 
primary rat neuronal cultures. NT4X and an isotype IgG2b control 
antibody were assayed to assess potential protective properties in an amyloid 
peptide induced cellular toxicity assay using primary rat cortical cultures. 
Cellular toxicity was measured using an LDH release assay and results 
converted to percentage inhibition of cell death compared to control wells 
(n=3 repeats on cell preparations from 3 separate rats). Values plotted are 
means +/− SEM. The NT4X antibody shows inhibition of AβpE3-42 and Aβ4-42 
induced toxicity but has no effect on the toxicity induced by full length Aβ1-
42.   
 
 
In vitro toxicity rescue of the Fab fragment of the NT4X was also 
studied in primary neurons using a calcein assay. Treating the cells 
with freshly prepared Aβ4-42 resulted in a dose-dependent reduction in 
cell viability. NT4X significantly rescued toxicity of Aβ4-42 (Fig 3.21). 







Figure 3.21. Cellular toxicity of N-truncated Aβ4-42 peptides and 
treatment effect of NT4X Fab fragment. In rat primary cortical neurons, 
Aβ4-42 peptide induced significant dose-dependent cellular toxicity. NT4X Fab 
treatment completely rescues toxic effects of freshly dissolved 1, 5 and 10 
μM Aβ4-42. (ANOVA, P<0.0001, F= 87.24, dF= 17). After ANOVA, the 
individual groups were subsequently analysed using Bonferroni multiple 
comparisons. (Abbreviation: ***, P<0.0001).  
 
3.6.  NT4X and Fab Fragment in vivo Rescue of Aβ 
Toxicity 
 
In order to study the therapeutic effects of NT4X and its Fab 
fragment in wild-type mice, the animals were given an 
intracerebroventricular (ICV) injection of freshly prepared 50pmol Aβ4-
42 and Aβ4-42 in combination with the NT4X antibody or the Fab 
fragment, respectively. Working memory was assessed using the Y-
maze (Fig 3.22). The alternation rate was significantly reduced after 
injection of Aβ4-42 reaching chance level (dashed line). In contrast, mice 
injected with Aβ4-42 and 1 pmol NT4X antibody behaved like vehicle 
controls and learned well (compared to Aβ4-42 injection; one-way 
ANOVA: p<0.05). The alternation rate in mice treated with 10 pmol 
NT4X further increased (compared to Aβ4-42 injection; one-way ANOVA: 
p<0.01). Furthermore, mice treated with Aβ4-42 and 10pmol Fab NT4X 
also showed no deficits in working memory and behaved like the 




Mice treated with only the NT4X antibody or its Fab fragment showed 
a similar alternation rate than mice treated with the vehicle control 
alone. Experiment was performed by SynAging (Nancy, France).   
Therefore, the NT4X antibody and its Fab fragment were able to 
rescue the learning deficits induced through Aβ4-42 injection in a dose-
dependent manner.   
Figure 3.22. Full-length and Fab fragment of NT4X rescue Aβ4-42 
induced working memory deficits in wildtype mice. (a,b) Working 
memory deficits were induced by intraventricular injection of Aβ4-42 as the 
mice performing at chance level (dashed line). Both treatment with (a) full-
length antibody and (b) Fab fragment rescued memory deficits in a dose-
dependent manner. Mice treated with the vehicle control and the vehicle in 
combination with full-length or Fab fragment of NT4X respectively 
demonstrated normal working memory performance. One-way analysis of 
variance (ANOVA) followed by Bonferroni multiple comparisons; n=6–8 per 






3.7.  Spatial Reference Memory Deficits in Homozygous 
Tg4-42 Mice 
 
Memory deficits have previously been described in homozygous 
Tg4-42 mice at 8 months of age (Bouter et al., 2013). In order to 
identify the onset of spatial reference memory deficits Tg4-42hom 
mice were analysed at six months (m) of age and compared to age-
matched wild type controls using the Morris water maze.  
All mice showed progressively decreased escape latencies over 
three days of cued training (Fig 3.23a; two-way repeated measures 
ANOVA, 6 m Non-treated (NT) and 6m Wild-type (WT): main effect of 
days: p < 0.00001). All mice showed comparable swimming speeds 
(Fig 3.23b).   
 
Figure 3.23. Cued training of the 6 months homozygous Tg4-42 water 
maze. Reveals that Tg4-42 exhibit intact eyesight and motor abilities. 
Homozygous Tg4-42 mice and WT littermate controls were examined at 6 
months of age. All mice showed progressively shorter escape latencies in 
response to training (main effect of days: p < 0.00001). Swimming speed did 
not differ between genotypes. Escape latencies and swimming speed: two-
way repeated measures ANOVA. n = 8-9 per group; data presented as mean 






Throughout the five days of acquisition training, both Tg4-
42hom mice and aged-matched WT mice, showed a significant 
decrease in the escape latencies (Fig 3.24). A significant main effect of 
days could be found for escape latencies (two-way repeated measures 
ANOVA, days: p=0.0291). Also, a significant difference was detected 
between the genotypes (two-way repeated measures ANOVA, genotype: 
p=0.0038). Since a significant difference in average swimming speed 
was also identified between genotypes (two-way repeated measures 
ANOVA, genotype: p=0.0073), distance travelled before reaching goal 
platform was also calculated to ascertain that genotype difference did 
not arise from swimming speed. Again, a significant effect of days 
could be found (two-way repeated measures ANOVA, days: p=0.0123) 
as well as a significant genotype difference (two-way repeated 






Figure 3.24. Acquisition training of the Morris water maze reveals that 
6 months Tg4-42hom mice perform inferior to WT controls. Homozygous 
Tg4-42 mice and WT littermate controls were examined at 6 months of age. 
Across the 5 days of acquisition both groups showed a significant decrease 
in the escape latencies and in distance travelled before reaching platform. 
(a,c) At 6 months Tg4-42hom performed significantly inferior to WT mice 
both in escape latency and distance travelled (b) A significant difference in 
swimming speed was detected between genotypes. (a)-(c). Escape latencies, 
distance travelled and swimming speed: two-way repeated measures ANOVA, 
(***p < 0.001, **p < 0.01, *p < 0.05. n = 8-9 per group; data presented as 
mean ± S.E.M; m = months.)  
 
48 hours after the last acquisition trial, a probe trial was 
conducted to assess spatial reference memory. Six-month-old Tg4-
42hom mice displayed no significant preference for the target 
quadrant as compared to WT controls that displayed a significant 
preference to the target quadrant (Fig 3.25a, one-way ANOVA followed 




O: p < 0.001). Since a significant difference in swimming speed was 
also identified between genotypes (Fig 3.25b, two-way repeated 
measures ANOVA, genotype: p=0.023), distance travelled in all 
quadrants was also assessed to confirm results. Again 6 months old 
Tg4-42hom displayed no preference for distance travelled in target 
quadrant as compared to WT group that preferentially covered more 
distance in target quadrant (Fig 3.25c, one-way ANOVA followed by 
Bonferroni’s multiple comparisons test for WT group, T vs. L, R and O: 
p < 0.001). Results are also evident in the group occupancy plots 
reflecting search strategy during the probe trial (Fig 3.25d) where the 
WT group shows preference for the target quadrant while 6 months 
old Tg4-42hom display a random search strategy.  
Taken together results indicate severe spatial memory deficits of 







Figure 3.25. Spatial reference memory deficits in 6 months old Tg4-
42hom mice shown in the probe trial of the Morris water maze. 
Homozygous Tg4-42 mice and WT littermate controls were tested at 6 
months of age. (a) Homozygous Tg4-42 mice did not show a preference for 
time spent in target quadrant. However, same-aged WT mice had a 
significant preference for the target quadrant (b) Swimming speed was 
significantly different between genotypes. (c) Homozygous Tg4-42 mice did 
not show a preference for distance travelled in target quadrant as compared 
to WT group that showed preferentially covered more distance in the target 
quadrant. (d) Group occupancy plots reflecting search strategy during the 
probe trial. (Abbreviations: T = target quadrant; L = left quadrant; R = right 
quadrant; O = opposite quadrant. Quadrant preference: ANOVA followed by 
Bonferroni multiple comparisons, ***p < 0.001. Swimming speed: two-way 





3.8.  Preventative Passive Immunization of Tg4-42hom 
Mice with NT4X and Fab 
 
3.8.1.  Rescue of spatial reference memory deficits  
 
Severe spatial reference memory deficits in Tg4-42hom were 
detected at 6 months of age. Therefore, 6-month-old Tg4-42hom mice 
that had received weekly injections with the full-length or Fab of NT4X 
antibody, and those injected with an IgG antibody control for a period 
of 12 weeks were assessed using the Morris water maze. All Tg4-
42hom treatment groups showed progressively decreased escape 
latencies in the cued training. A significant main effect of days could 
be found for escape latencies (Fig 3.26a, two-way repeated measures 
ANOVA, days: p < 0.0001). All mice showed comparable swimming 
speeds (Fig 3.26b).  
The cued training revealed that all mice had an intact vision 
and appropriate motor abilities to swim.  
  
 
Figure 3.26. Cued training of the water maze reveals that Tg4-42 
treatment groups exhibit intact eyesight and motor abilities. 
Homozygous Tg4-42 treatment groups were examined at 6 months of age. All 
mice showed progressively shorter escape latencies in response to training. 
Swimming speed did not differ between treatment groups. Escape latencies 
and swimming speed: two-way repeated measures ANOVA. n = 10-13 per 




All groups showed a significant decrease in escape latencies over 
the five days of acquisition training (Fig 3.27a, two-way repeated 
measures ANOVA, days: p < 0.0001). Different treatments did not 
have a significant effect on escape latency. Swimming speed between 
groups was comparable (Fig 3.27b).  
 
Figure 3.27. Spatial learning was assessed in the acquisition training of 
the Morris water maze. Tg4-42hom treatment groups were examined at 6 
months of age. (a) Across the 5 days of acquisition all groups showed a 
significant decrease in escape latency. (b) Swimming speed did not differ 
between treatment groups. Escape latencies: two-way repeated measures 
ANOVA, effect of days: p < 0.0001. n = 10-13 per group; data presented as 
mean ± S.E.M.  
 
48 hours after the last acquisition trial, a probe trial was 
conducted to assess spatial reference memory. No quadrant 
preference was found for IgG control treatment group. Both full-length 
and Fab NT4X immunized Tg4-42hom mice displayed a significant 
preference for the target quadrant, as indicated by the percentage time 
spent in different quadrants of the pool (Fig 3.28a, one-way ANOVA, 
full-length NT4X: p < 0.01 T vs. L and O quadrant; Fab: p<0.001 T vs. 
L and O, T vs R p <0.01 quadrants). Swimming speed did not differ 





This indicates that both the full-length NT4X antibody and the 
Fab fragment of NT4X were able to rescue spatial reference memory 
deficits in 6 months old Tg4-42hom mice.  
No significant difference in Cued training, Acquisition training 
or the Probe trial test were found between the Non-treated 6 months 
old Tg4-42hom (Fig 3.28) and the IgG control treatment group (Fig 
3.28).    
 
Figure 3.28. Passive immunization rescues spatial reference memory 
deficits in NT4X and Fab treated Tg4-42hom mice shown in the probe 
trial of the Morris water maze. Homozygous Tg4-42 mice were tested at 6 
months of age. (a) Tg4-42hom IgG treated control mice did not show a 
preference for the target quadrant. However, NT4X and Fab treated mice 
showed significant preference for the target quadrant. (b) Swimming speed 
did not differ between the groups. (Abbreviations: T = target quadrant; L = 
left quadrant; R = right quadrant; O = opposite quadrant. Quadrant 
preference and swimming speed: One-way analysis of variance (ANOVA) 
followed by Bonferroni multiple comparisons, ***p < 0.001; **p < 0.01. n = 
10-13 per group; data presented as mean ± S.E.M.) 
 
3.8.2.  Deceleration of neuron loss  
 
In order to study the potential therapeutic effect of NT4X on the 
observed neuron loss in 6 months old Tg4-42hom the neuron 




The number of neurons was compared between 6-months-old 
Tg4-42hom immunized with full-length NT4X or Fab NT4X and a 
control group immunized with an IgG2b antibody control. Stereology 
revealed a significant treatment effect (Fig 3.29, one-way ANOVA, 
treatment: p = 0.0007). Following ANOVA, the individual groups were 
then analysed using Dunnett’s multiple comparisons. Compared to 
IgG control injected mice (mean=136,170; SEM±5455), the neuron 
numbers in Tg4-42hom were significantly increased after 
immunization with full length NT4X (mean=160,156; SEM±5096) and 
Fab (mean=165,844; SEM±4717) (Fig 3.29; one-way ANOVA: NT4X vs 
IgG injected: p<0.01; Fab vs IgG injected: p<0.001).  
NT4X immunized Tg4-42 mice displayed 14.97% more neurons 
in the CA1 layer of the hippocampus than control IgG treated mice. In 
comparison, Fab immunized mice displayed 17.89% more neurons as 
compared to control IgG treated mice.  
 
Figure 3.29. NT4X and Fab mitigate neuron loss in Tg4-42hom mice. 
Quantification of neurons in the CA1 of 6-months-old Tg4-42hom using 
unbiased stereology. Tg4-42hom mice that received weekly injections with 
the NT4X antibody or its respective Fab fragment and an IgG control group 
for a period of 12 weeks were analysed at 6 months of age. Tg4-42hom mice 
immunized with NT4X full length or Fab fragment both displayed 
significantly more neurons than age-matched IgG control injected mice. One-
way analysis of variance (ANOVA) followed by Dunnett’s multiple 
comparisons; n=10–14. (**p<0.01; ***p<0.001; data presented as 








4.1.  N-Truncated Amyloid Beta 4-x: The Target 
 
4.1.1.  Properties of Aβ4-x 
 
Part of this work has been dedicated to confirm N-truncated 
amyloid beta starting at position 4 (phenylalanine) as a viable target in 
AD research and therapy. To this end, the aggregation properties of 
Aβ4-x, under reducing conditions, was demonstrated using the N-
terminal specific antibody NT4X (Fig 3.18). As previously reported by 
Jan and colleagues for full length Aβ (Jan et al., 2008), we  also mark 
that the aggregation  properties of N-terminally truncated AβpE3-x and 
Aβ4-x is affected by the carboxyl-terminal length of the peptide. 
Wherein, under reducing conditions, AβpE3-40 and Aβ4-40 migrate as 
monomers (4 kDa) and dimers (8 kDa), in contrast to AβpE3-42 and Aβ4-
42, both of which exhibited higher molecular weight aggregations of 
trimer (12 kDa) and tetramers (16 kDa) in addition to monomers and 
dimers. We had previously shown that in contrast to full length Aβ1-42, 
which tends to remain in equilibrium with its monomeric state for 
longer, AβpE3-42 and Aβ4-42 tend to form stable oligomers faster (Bouter 
et al., 2013). It has previously also been reported that the aggregation 
propensities of Aβ may be directly affected by varying either terminal 
length of the peptide (Jan et al., 2008; Jarrett et al., 1993; Pike et al., 
1995).   
 
4.1.2.  Aβ4-x as a target 
 
The neurotoxicity of N-terminal truncated variants of Aβ has 
been known for over two decades (Pike et al., 1995). First 
demonstrated by Pike and colleagues, it was later suggested that they 




(Russo et al., 2002). These observations were recently extended by our 
lab, showing that AβpE3-42 and Aβ4-42 have specific structural features 
that render their soluble aggregates neurotoxic. The stable aggregates 
formed by AβpE3-42 and Aβ4-42 were different in size and morphology 
than those formed by full length Aβ1-42, as shown by far UV CD 
spectroscopy, dynamic light scattering and NMR spectroscopy (Bouter 
et al., 2013).  
The exact levels of N-truncated Aβ peptides that comprise a part 
of the total Aβ pool of AD patient’s has been hard to determine. This is 
mostly due to a variation of methodology and tools used to extract this 
information. It is in agreement nonetheless, that N-truncated Aβ 
peptides appear during Alzheimer disease progression (Bayer & 
Wirths, 2014). It is of interest that intraneuronal Aβ has also been 
reported to be N-truncated and that Aβ4-x, starting with phenylalanine 
is the variant that is mostly reported in pre-symptomatic AD cases  
(Gouras et al., 2000). In good agreement, N-terminal truncated 
variants (beginning with position 4 “Phenylalanine”, position 5 
“Arginine”, position 8 “Serine”, position 9 “Glycine” and position 3 
with a pyroglutamyl residue) comprised the first stage of amyloid 
deposition in non-demented individuals. At this stage all Aβ variants 
detected were not truncated at their C- terminus (Aβx-42) (Sergeant et 
al., 2003).  
Masters and colleagues had first reported that Aβ4-x was a 
component of amyloid deposits analyzed from human AD brains 
(Masters et al., 1985). In agreement with these findings, cotton wool 
plaques in patients with familial AD, were found to harbor high 
amounts of Aβ4-42 (Miravalle et al., 2005). Along those lines, we have 
also shown that Aβ4-x intraneuronal accumulation precedes that of 
Aβpe3-x in the established 5XFAD mouse model (Antonios et al., 2013).  
To that end, the Tg4-42 mouse model has been recently 
established (Bouter et al., 2013) and validated as an advantageous 




for its intraneuronal accumulation, and permits the study of a 
previously neglected therapeutic option in AD; the Aβ4-42 peptide.   
 
 
4.1.3.  The Tg4-42 model: Aβ4-42 in vivo  
 
N-truncated Aβ peptides have been reported in several AD 
mouse models. A 2D electrophoresis analysis combined with mass 
spectrometry, has enabled the detection of a wide variety of N-
truncated Aβ variants in APP/PS1KI mice. At 2.5 months Aβ2/3-42, 
Aβ4/5-42 and Aβ8/9/10/11-42 were found, and the appearance of AβpE3-x 
was noticeable from 6 months of age (Casas et al., 2004). Another 
typical AD mouse model to exhibit N-truncated Aβ peptides is the 
5XFAD model. Confirmed variants in the 5XFAD model have been 
AβpE3-40/42, Aβ4-40/42 and Aβ5-40 (Antonios et al., 2013; Guzman et al., 
2014; Jawhar et al., 2012; Oakley et al., 2006; Richard et al., 2015). 
Other models reported to have N-truncated Aβ peptides are the 
PDAPP, Tg2576 and APP23 mouse models, all of which also exhibit 
intracellular Aβ accumulation (Chapman et al., 1999; Games et al., 
1995; Hsiao et al., 1996; Kelly et al., 2003; Masliah et al., 1996; Rijal 
Upadhaya et al., 2013; Rockenstein et al., 1995; Sturchler-Pierrat et 
al., 1997).  
The disadvantage that had previously accompanied transgenic 
mouse models of AD was the fact that they relied overly on the over-
expression of APP or the expression of mutations that affected the 
processing of APP. This has led to models that mostly reflect the 
familial form of AD from which these models were inspired. They also 
neglected contributions from N-truncated Aβ forms, which were found 
in small amounts relative to full length Aβ1-40/42 in these models. 
Although highly beneficial for basic research into the etiology of AD 
disease, the models might not provide perfect tools for therapeutic 
intervention that may be translated into the clinic.  
To this end, our lab has recently developed the Tg4-42 mouse 




exhibits some aspects of AD pathology without the reliance on APP 
overexpression or processing. Aβ4-42 intraneuronal accumulation 
eventually leads to neuron loss and spatial memory deficits, without 
extracellular Aβ accumulation in the form of plaques (Bouter et al., 
2013). This further boosts our previous hypothesis on the importance 
of intraneuronal Aβ being the trigger for respective downstream 
pathological events (Wirths et al., 2004).  
 
4.1.4.  Neuron loss and spatial reference memory: Age-
dependent decline 
 
Efforts to model AD-relevant cognitive deficits in mouse models 
have met with partial success (Kobayashi & Chen, 2005). The 
hippocampus is one of the first and most severely touched brain 
regions in AD patients. Various mouse models have tried to assess 
reference memory as this particular memory function is highly specific 
for the hippocampal region (West, 1993). We have previously shown 
that at 8 months of age, homozygous Tg4-42 mice have developed 
severe hippocampus neuron loss and spatial reference memory 
deficits (Bouter et al., 2013). It was of interest to the current work, to 
determine the onset of neuron loss and subsequent spatial reference 
memory deficit in the Tg4-42 homozygous mice.  
We show that the Tg4-42hom mice exhibit an age-dependent 
neuron loss in the CA1 region of the hippocampus where neuron loss 
starts at 4 months of age and gradually decreases with age to reach 
50% at 6 months of age and 64% at 8 months of age (Antonios et al., 
2015). More importantly, this coincides with age-dependent spatial 
memory deficits where the mice at 6 months of age have developed a 
severe spatial reference memory deficit as compared to aged matched 
WT control mice both in acquisition training and in the probe trial of 
the Morris water maze (Fig 3.24 and Fig 3.25). In rats,  spatial 
memory impairment has been reportedly linked to bilateral dorsal 




lesions that encompassed 30-50% of total volume and worsened 
dramatically as lesion size increased above 50% of total hippocampal 
volume (Broadbent et al., 2004). At 5 months of age, the Tg4-42hom 
mice suffer from a 43% neuron loss in the CA1 and signs of mild 
spatial reference memory deficits as compared to 6 months where 
neuron loss has increased to 50% and spatial reference memory 
deficits have become severe (Antonios et al., 2015). This is in 
agreement with other findings which have shown that a significant 
neuron loss in the hippocampus may still be compensated as only 20-
40% of the total hippocampus is required for effective spatial learning 
(Moser et al., 1995).  
Other studies have also shown an age dependent reference 
memory decline in transgenic mouse models of AD. Westerman and 
colleagues have shown that spatial reference memory deteriorates 
progressively after 6 months of age, as shown in a Morris water maze, 
in Tg2576 mice. Severe deficits, however are only apparent after 12 
months of age (Westerman et al., 2002). Another study utilized the 
radial arm water maze to show an age dependent reference memory 
decline in APP/PS1 KI mice. Again, memory deficits are only 
observable starting at 11 months of age and become severe at 15 
months (Webster et al., 2013).  
This goes to show the importance of the Tg4-42hom mice as a 
tool for AD therapeutic intervention. Since the mice already display 
tremendous neuron loss and reference memory deficits at 6 months of 
age, the timeline for therapeutic intervention is drastically cut down 
as compared to other mouse models.  
 
4.2.  NT4X: The Therapeutic Tool 
 
Since Aβ4-40 peptides were found to form stable aggregates in 
solution (Bouter et al., 2013), we have used them in order to generate 




The novel oligomeric Aβ specific antibody NT4X was generated 
by immunizing three Balb/c mice with unconjugated Aβ4-40. After 
preparation of the lymph nodes they were fused with the myeloma cell 
line P3-X63-Ag8 for generation of the hybridoma cells. After fusion, 
the hybridoma cells were screened by an enzyme-linked immune-
absorbent assay (ELISA) for an antibody that recognizes Aβ4-10/40 
peptides but not the C-terminal end of amyloid beta, thus not 
recognizing the Aβ36-40 peptide. Positive antibody clones were further 
screened by IHC staining of human brain sections. The intention of 
the screening procedure was to find a clone that would not 
preferentially bind to amyloid plaques thereby identifying NT4X 
(Antonios et al., 2013).  
 
4.2.1.  Antibody purification  
 
The hybridoma clone B4C11 was subsequently chosen as it fit 
all previously mentioned selection criteria for the desired antibody. 
Although small-scale cultures of the hybridoma cell line were 
maintained in media containing serum, the need for large-scale 
antibody purification (Fig 3.1) required the conditioning of the cell line 
with a serum-free culture media. This was done to achieve higher 
purity of antibody purified. It is well known that serum containing 
media would contain high titers of antibody from  the host organism 
thus interfering with purification (Howard & Kaser, 2013).  
For the purpose of this study, large amounts of purified 
antibody were necessary. Since the small-batch production of 
milligram amounts of antibody was not sufficient, we turned to 
culture using bioreactors to improve the amount and efficiency of 
purification. It has been previously reported that a perfusion culture 
of hybridoma cells drastically increases the number of viable cells 
(cells/mL) and thus leads to higher overall amounts of antibody 
produced (mg/L) per liter of culture media (Tang et al., 2007). Our 




upwards of 50-60 mg/mL as compared to 30 mg/mL from previous 
purifications using traditional methods. 
Tracking of antibody purification reveals a high degree of purity 
was achievable through the designed purification protocol, while the 
presence of both heavy and light chains confirm antibody presence 
(Fig 3.3 and Fig 3.4).  
 
4.2.2.  Antibody characterization 
 
In order to determine the specificity of the purified NT4X 
antibody against Aβ species, it was utilized as a primary antibody in 
western blot analysis of various N-truncated and full length Aβ 
species. Since the antibody itself was raised against unconjugated 
Aβ4-40, it was no surprise that it detected Aβ4-40 and Aβ4-42 as shown 
under reducing conditions (Fig 3.18). The antibody however also 
recognized the pyroglutamate modified N-truncated Aβ species as well, 
recognizing both AβpE3-40 and AβpE3-42 peptides under reducing 
conditions (Fig 3.18). This is further corroborated by results obtained 
from a similar experiment performed under native conditions where 
the antibody also recognized N-truncated Aβ species (Antonios et al., 
2013).  
It is worth noting that, as compared to the IC16 antibody, the 
NT4X antibody does not recognize full length Aβ1-40/42 as we have 
shown in both reducing and native conditions. This is due to the fact 
that the antibody binds most strongly to the phenylalanine as position 
4 of Aβ, as demonstrated by a pepscan analysis, and the additional 
peptides contained in full length Aβ might be blocking it from binding 
to its preferred site (Antonios et al., 2013). 
Previously characterized antibodies have been raised against 
pyroglutamate modified N-truncated Aβ species (Frost et al., 2012;  
Wirths et al., 2010), most have been raised against full length Aβ 
(Bard et al., 2000; Dodart et al., 2002; Wilcock et al., 2004c) and the 
NT4X antibody is unique in its ability to recognize both AβpE3-x and 




30 ng of Aβ4-42, corresponding to a sensitivity of approximately 7 
picomoles under reducing conditions (Fig 3.19).   
We further show that the NT4X antibody, as previously selected 
to be, reacts to a very low extent with extracellular plaques in human 
AD tissue (Antonios et al., 2013). Our working group has further 
expanded and recently confirmed the previous result in comparison to 
the biosimilar antibodies of Bapineuzumab, Crenezumab, 
Solanezumab in sporadic AD cases and mouse models (Bouter et al., 
2015). Similarly, this description has been valid for the confirmation 
specific AβpE3-x antibody 9D5 (Wirths et al., 2010). In murine tissue 
the NT4X reacts both with intracellular and extracellular Aβ and we 
were able to show that in the homozygous 5XFAD model (Richard et 
al., 2015),  that the intraneuronal accumulation of Aβ4-x precedes that 
of AβpE3-x, underlying a fact which was not previously presented 
(Antonios et al., 2013).  
 
4.2.3.  In vitro and in vivo target engagement and rescue  
 
To further out work in characterizing the NT4X antibody and its 
therapeutic potential, collaborators at SynAging (Nancy, France) and 
MRC Technology (London, United Kingdom) have performed in vitro 
and in vivo target engagement and rescue assays with the NT4X 
antibody.  
To go in parallel with our results showing that the NT4X 
recognized both N-truncated AβpE3-x and Aβ4-x species, but that full 
length Aβ1-x (Antonios et al., 2013), NT4X was also found to rescue the 
toxicity resulting from both AβpE3-42 and Aβ4-42 in primary rat neuronal 
cultures (Antonios et al., 2015). Even when antibody concentration is 
increased well above 1:1 molar ratio (antibody:peptide) the NT4X does 
not rescue toxicity induced by full length Aβ1-42 as measured by an 
LDH release assay. Not surprisingly, the antibody seems also to 
rescue Aβ4-42 preferably as it requires only 133.7 µg/ml of NT4X to 
reach 50% of cell death inhibition caused by 10 µM of Aβ4-42, as 




death inhibition (50%) caused by a lesser amount of 5 µM AβpE3-42 (Fig 
3.20). The molecular mechanism of Aβ-induced neuronal cell death is 
not well understood, though studies have reported the involvement of 
reactive oxygen species (ROS) in Aβ induced neuronal cell death (Behl 
et al., 1995). It was more recently determined that Aβ induces 
neuronal cell death through ROS mediated ASK1 activation, and the 
authors have proposed ASK1 as a therapeutic target for prevention 
and treatment of AD (Kadowaki et al., 2005).  
It was previously demonstrated that Aβ peptide ICV injection 
induced short term memory impairment in rats (Stepanichev et al., 
2003). Recently, we have shown that N-truncated Aβ variants 
(including Aβ4-42) induce working memory deficits in wild type mice 
(Bouter et al., 2013). In order to demonstrate NT4X in vivo target 
engagement, a similar experimental setup was reproduced. ICV 
injection of Aβ4-42 caused a working memory deficit as demonstrated 
by a Y-maze, the effect of which is completely rescued by the NT4X 
antibody in a dose dependent manner (Fig 3.22a). The work is 
essential in showing that the NT4X is capable of target engagement 
and rescue of Aβ4-42 in vivo, under physiological conditions where the 















4.3.  Passive Immunization of the Tg4-42hom AD Model 
Using NT4X and its Fab 
 
4.3.1.  Timeline and dosage 
 
Pre-clinical passive immunization studies usually differ in at 
least one of the following parameters: Dosage/time course, animal 
model employed and antibody used for immunization. Previous 
therapeutic and preventative passive immunization trials against N-
truncated Aβ peptides have attempted both subcutaneous and 
intraperitoneal administration and opted for a dosage of 12.5 mg/kg 
body weight (DeMattos et al., 2012; Frost et al., 2012). Moreover, 
mouse models frequently used in immunization studies such as the 
Tg2576 and PDAPP exhibit a difference in the morphology and 
stoichiometry of Aβ deposits (Fryer et al., 2003; Hsiao et al., 1996; 
Sasaki et al., 2002). This goes to reflect the difficulty in comparing 
different preclinical trials. It also reflects as to why the outcome of 
clinical studies poorly reflected the results from pre-clinical 
immunizations (Lannfelt et al., 2014).  
At 4 months of age, neuron loss in the CA1 region of the 
hippocampus in the homozygous Tg4-42 is marked with a 17% loss, 
and precedes the appearance of behavioral deficits As the mice are 
still pre-symptomatic at that stage, still capable of learning and have 
an intact reference memory till the age of 4 months in a MWM, we 
opted for the purpose of this study to perform a preventative passive 
immunization. For early intervention in AD by passive immunization, 
it would be necessary to identify patients inclined to more likely 
develop cognitive impairment. Though this is currently not possible, it 
has driven research into the defining of preclinical biomarkers in AD 
(Fiandaca et al., 2014).  
The dosage, administered intraperitoneally, chosen for this 
study was 10 mg/kg body weight to be injected weekly. In this 
treatment window, mice would be immunized with the NT4X antibody 




symptomatic, for the duration of 12 weeks reaching an age of 6 
months. This has allowed us to examine the preventative therapeutic 
effect of the NT4X at an endpoint where the mice usually exhibit 
reference memory deficits (Fig 4.1).  
 
Figure 4.1. Passive Immunization timeline of Tg4-42. Onset and 







4.3.2.  Rescue of neuron loss 
 
Almost all pre-clinical immunization studies, have relied on Aβ 
burden as a measurable outcome.  While some approaches were 
therapeutic, with immunization starting after the onset of plaque 
pathology, other attempted a preventative approach. In therapeutic 
trials, some studies have reported no clearance of existing plaques 
(Dodart et al., 2002; Levites et al., 2006), while other report limited 
clearance (Tucker et al., 2008). Not all trials were unsuccessful 
however, with several studies suggesting a significant reduction in 
pre-existing plaques (Frost et al., 2012; Wilcock et al., 2004b). On the 
other hand, preventative passive immunization has been more 
successful, with numerous reports of significant inhibition of plaque 
pathology (Bard et al., 2000, 2003; Bussiere et al., 2004; Frost et al., 
2012; Lord et al., 2009).  
In spite of the previous, it is well known that Aβ levels do not 
necessarily correlate with the therapeutic outcome. Reversal of 
memory deficits in mice, for example, has been shown in an AD 
mouse model, even though the preclinical passive immunization study 
did not reduce brain Aβ burden (Dodart et al., 2002). On the other 
hand, passive immunization of APPswe/PS1ΔE9 transgenic mice with 
an antibody against the N-terminus of pyroglutamate Aβ3-X 
significantly reduced total plaque deposition in the hippocampus and 
cerebellum, without however, affecting  Aβ levels as measured by 
ELISA (Frost et al., 2012).  
In this study, we propose a new measurable outcome for the 
assessment of passive immunization in the homozygous Tg4-42 mice. 
As previously discussed, the Tg4-42 mice exhibit an early loss of 
neuron in the CA1 region of the hippocampus. Preventative passive 
immunization using the NT4X antibody or its Fab fragment, was able 







4.3.3.  Rescue of reference memory deficits 
 
While most passive immunization studies do not tackle the 
issue of behavioral deficits, most likely due to the fact that results 
were negative, others have reported findings. The rescue of memory 
deficits has been reported for a variety of mouse models such as the 
5XFAD (Wirths et al., 2010), PDAPP (Dodart et al., 2002) and the 
Tg2576 (Wilcock et al., 2006; Wilcock, et al., 2004a). Is it important to 
mention that some have even reported the reversal of memory deficits 
with no reduction in plaque load, further asserting the fact that 
plaque burden and behavioral deficits are not correlated (Dodart et al., 
2002). Moreover, most mouse models in which an amelioration of 
behavioral deficits is reported, are APP overexpressing or enzymatic 
mutation of APP related models, reflecting more cases of familial AD 
than those of sporadic AD.  
We were able to achieve a reversal of spatial reference memory 
deficits in the Tg4-42 homozygous mice after passive immunization 
with the NT4X antibody and its Fab fragment. The preventative 
treatment, allowed for mice to maintain an intact spatial reference 
memory, as one exhibited in the pre-symptomatic phase (Fig 3.28). 
This goes in line with the direction of on-going clinical trials where 
most passive immunization trials are now focused on prevention and 
very early treatment of AD (Lemere, 2013).  
 
4.3.4.  Mechanism of NT4X passive immunotherapy 
 
The cornerstone theory of Aβ engagement, suggested that 
antibodies may act catalytically to prevent Aβ aggregation or dissolve 
its preformed aggregates (Solomon et al., 1997). This was later on 
supported by the first active immunization trials which demonstrated 
plaque removal in response to immunization with Aβ1-42 aggregates, 
allowing the immune system to develop anti- Aβ antibodies (Schenk et 
al., 1999). Though active immunization per-say was abandoned due to 




concerning removal of deposited amyloid peptides. It is estimated that 
less than 1% of antibody injected in passive immunization crosses the 
BBB to reach its target, treatment effects have nonetheless been 
positive (Lemere, 2013). Bapineuzumab was the first humanized 
antibody in clinical trials, its murine predecessor 3D6 target full 
length Aβ1-42. It failed however to improve clinical outcomes in a phase 
III placebo-controlled study of patients with mild to moderate AD 
(Salloway et al., 2014). Studies have even suggested that the 
solubilization of fibrillar Aβ may have a noxious effect (Benilova et al., 
2012; Haass et al., 1994). In this study, we circumvent this issue by 
the use of the Tg4-42 model, which does not exhibit Aβ deposits in the 
form of plaques, and allows for target engagement of the NT4X 
antibody without the repercussions faced by other passive 
immunotherapy studies which employed models harboring plaque 
pathology.  
A different hypothesis for antibody Aβ clearance, the peripheral 
sink hypothesis, does not require the penetration of the BBB. It has 
been shown that Aβ can be rapidly transported to the periphery 
(Ghersi-Egea et al., 1996; Shibata et al., 2000). In this light, it has 
been proposed that a shift in Aβ equilibrium, driving a higher efflux 
from the central nervous system would allow peripherally circulating 
antibodies to facilitate Aβ clearance (Bacskai et al., 2002; Das et al., 
2003). In reality however, reports have been contradictory. While some 
studies utilizing the murine predecessor of Solanezumab, the m266 
antibody, have reported an Aβ/m266 complex in the plasma and 
cerebrospinal fluid of treated PDAPP mice, thus supporting the 
peripheral sink hypothesis (Dodart et al., 2002b). Other studies have 
reported that the m266 neutralizes intracerebral rather than 
peripheral Aβ (Yamada et al., 2009).  
Microglial activation in immunotherapy has been suggested as a 
key player in the clearance of Aβ (Wang et al., 2011). The mechanism 
proposed that the clearance of amyloid deposits occur via an 




therapeutic antibody bound to Aβ (Bard et al., 2000). Results obtained 
in this study, do not support this hypothesis, as the passive 
immunization with the Fab fragment of the NT4X antibody, resulted in 
the same therapeutic effect of the full length antibody itself in 
mitigating neuron loss and reversing spatial reference memory deficits 
(Fig 3.29 and Fig 3.28). Along those lines, another study using Tg2576 
APP mice that were further engineering as Fc receptor-gamma chain 
knock-outs, still demonstrated an effect of anti-Aβ antibodies on Aβ 
deposition (Das et al., 2003), disproving the need for Fc receptor 
mediated phagocytosis.  
This study has been able to discuss several aspects of the 
treatment mechanism in AD passive immunotherapy. Primarily, we 
show that mouse models of AD needn’t harbor plaque pathology and 
that the Tg4-42 mouse model presents a chance to tackle soluble Aβ4-
42 aggregates of as possible therapeutic targets. We have introduced 
another paradigm in terms of measurable pre-clinical outcome for 
passive immunotherapy; neuron loss, and have demonstrated that the 
Fab fragments of antibodies are viable options for therapy.  
 
4.4.  Outlook in Immunotherapy 
 
4.4.1.  Autoantibodies against Aβ 
 
The presence of natural antibodies against Aβ has been reported 
in plasma samples and the cerebrospinal fluid of both AD patients 
and healthy controls (Britschgi et al., 2009). One such antibody 
presently in clinical trials is Aducanumab (Biogen). The most recent 
developments at the AD/PD conference (March 2015) reported interim 
analysis of first data sets from Aducanumab (Biogen). Developed from 
aged, cognitively healthy, donors using reverse translational medicine, 
it is a fully human IgG1 monoclonal antibody against a 
conformational epitope found on Aβ. Results have so far been 
promising with a dose dependent reduction in amyloid deposition in 




Association International Conference (AAIC) in August 2015, the 6 
mg/kg immunotherapy group was numerically reported to be closer to 
the 1 mg/kg than the 3 or 10 mg/kg group, in the mini-mental state 
examination (MMSE), but overall dose dependence remained 
significant. Phase III trials began in August 2015 and are set to run 
till 2022 (Alzforum.org).   
 
4.4.2.  Passive immunotherapy and vascular pathology 
 
A diet deficient in folate and vitamins B6and B12, has been 
reported to cause vascular cognitive impairment in WT mice (Sudduth 
et al., 2013). APP/PS1 mice, on a similar diet as previously 
mentioned, had a remarkable redistribution of Aβ to the vasculature 
from the parenchyma, although total Aβ levels remained unchanged. 
The mice also worsened as compared to control groups, in a radial 
arm maze (Sudduth et al., 2014). This has raised questions regarding 
the co-morbidity effect of passive immunotherapy and vascular 
pathology. Aβ-related imaging abnormalities (ARIA), which have been 
linked to vasogenic edema, were part of the demise of the 
Bapineuzumab program, and are being investigated in the ongoing 
trials with Aducanumab as well (Alzforum.org).  
 
4.4.3.  Intrabodies in immunotherapy 
 
Intracellular antibodies, or Intrabodies, are small, usually 
single-chain antibodies that are able to penetrate cells through the 
use of viral or other types of vectors. They are designed to designed to 
bind and inactivate target molecules inside cells  (Chen et al., 1994).  
The use of protein engineering, has further allowed the targeting 
of intrabodies to specific subcellular compartments. By adding a 
KDEL amino acid motif, targeting the antibody to the endoplasmic 
reticulum, the scFvA13 intrabody, which only recognizes Aβ in a 
sequence and confirmation selective manner, a study has been able to 




antibody (Meli et al., 2014). It was previously shown that 7PA2 cells 
produce large quantities of Aβx-42 and exports various forms of the 
peptide out of the cell (Walsh et al., 2005). Meli and colleagues are 
now investigating, using in vivo experiments, the targeting of the 
scFvA13 intrabody to the hippocampus of AD mouse models 
(Alzforum.org).   
 
4.5.  Crystallization of NT4X Fab and Target Peptide 
 
4.5.1.  Generation of Fab fragment 
 
In order to study the antibody: antigen binding properties of the 
NT4X antibody, the Fab fragment of the antibody had to be generated 
and ensured to be functional. Antibody subclasses exhibit diverse 
physical properties and show a substantial difference in their 
susceptibility to cleavage sites. Experimental parameters must be 
examined and adjusted for each individual subclass to ensure a 
complete digestion and more importantly a homogenous one. Antibody 
fragments have been routinely obtained by papain digestion. It has 
been suggested that the monitoring of antibody papain digestion by 
electrospray ionization mass spectrometry is of benefit (Bennett et al., 
1997). Initial results from antibody digestion with papain resulted in a 
heterogeneous mix of Fab subtypes and that of over digested products 
(Fig 3.5). The separation of resulting fragments was not possible via 
size exclusion chromatography nor through ion exchange 
chromatography (Fig 3.6).  
Although it was believed that the digestion of antibody 
fragments using pre-activated papain will result in the generation of 
F(ab’)2 fragment (100 kDa), it was later suggested that a closer 
monitoring of digestion conditions with regard to antibody subtype 
can result in a homogenous digestion resulting in an Fab fragment 
using pre-activated papain (Adamczyk et al., 2000). Our results are in 




a homogenous digestion of the NT4X antibody, resulting in a more 
pure Fab fragment (Fig 3.8).   
 
4.5.2.  Fab functional in vitro and in vivo 
 
In order to ensure the Fab fragment of the NT4X antibody has 
the same binding and functional properties as its full-length 
counterpart, our collaborators in Synaging have performed in vitro and 
in vivo toxicity rescue assays. The in vitro cellular toxicity assay using 
the Fab fragment, demonstrates the capability of the Fab fragment to 
bind and rescue the toxicity caused by Aβ4-42 in a dose dependent 
manner (Fig 3.21). On the other hand, an in vivo assay has 
demonstrated the Fab’s ability to rescue an Aβ4-42 induced working 
memory deficit in WT mice, as tested by a Y-maze alteration assay (Fig 
3.21b).The experiments demonstrate that the NT4X Fab is functional 
and exhibits similar binding capabilities as the full-length antibody. 
We have also used the Fab in passive immunization of the Tg4-42 
mice where it has demonstrated an ability to bind its target in an AD 
mouse model and rescue both neuronal loss and spatial reference 
memory deficits (Antonios et al., 2015).  
 
4.5.3.  Crystallization conditions 
 
To examine the structural basis of NT4X binding to Aβ, we 
endeavored to isolate the NT4X as a Fab fragment in complex to the N-
truncated Aβ4-19 peptide and went further to crystallize the complex. 
Initial screening for crystallization conditions tackled both matters of 
appropriate conditions and that of protein concentration (Chayen & 
Saridakis, 2008). Initial crystals obtained were of the unconjugated 
Fab fragment of the NT4X (Fig 3.12) and SDS-PAGE followed by silver 
staining confirmed that crystals observed were of respective size 





We next pursued the crystallization of the Fab: Aβ4-x peptides 
complex. Several Aβ C-terminal lengths were tested, including: Aβ4-10, 
Aβ4-19 and Aβ4-22. Crystallization was successful using the Fab: Aβ4-19 
complex. The corresponding peptide sequence of Aβ4-19 is the 
following:  
Phe4 - Arg - His - Asp - Ser - Gly - Tyr - Glu - Val - His - 
His - Gln - Lys - Leu - Val – Phe19 
Initial crystals of the Fab: Aβ4-19 complex grew in PEG 2000 
MME. Though some were amorphous in shape (Fig 3.14b,c), others 
were overlapping crystals (Fig 3.14a) of a distinct nature that were 
used to develop screening grids in conjunction with seeding. Seeding 
in crystallization, is used to bypass excess nucleation. By introducing 
ready-made nuclei directly into the metastable zone, the presence of a 
limited number of nuclei may ensure growth into larger single crystals 
(Bergfors, 2003; Chayen, 2003.) Our results demonstrate the previous 
by (Fig 3.15 and Fig 3.16). We also report an improvement in the 
diffraction potential of crystals, where successive rounds of seeding 
have improved the diffraction resolution limit from 9Ǻ (Fig 3.15a) and 
5Ǻ (Fig 3.15b) to 2.8Ǻ (Fig 3.16b). It is worth noting that all crystals 
from respective seeding rounds grew in very similar conditions 
consisting of PEG (3000, 6000 or 8000) as precipitant and (0.1M, pH 
═ 4.6) sodium acetate trihydrate.  
The crystallization conditions of the NT4X Fab: Aβ4-19 complex, 
is very comparable to previously published data. Crystals of the WO2 
antibody, the first anti-Aβ antibody to be crystallized complexed with 
Aβ, was crystallized in 25% PEG 400, 100 mM MES pH 6.5 (Wun et 
al., 2008). Later on, Bapineuzumab, the first anti-Aβ antibody to go 
into AD passive immunotherapy, was crystallized in complex with 






4.5.4.  Crystallization of clinically relevant antibodies 
 
It is the future objective of this work, to determine the molecular 
basis of the Aβ recognition of NT4X. In context of clinical relevance, 
this will allow the development and humanization of the NT4X in a 
way which enhances its binding to its target. A report has previously 
demonstrated the conservation of antigen contact residues and 
conformation of antigen recognized between the 3D6 antibody and its 
humanized counterpart Bapineuzumab (Feinberg et al., 2014). It has 
been previously demonstrated that the introduction of mutations to 
an antibody, following information gathered from its crystallographic 
analysis, induced a 500 fold improvement in affinity for a helical 
peptide ligand. The mutated residues did not actually interact with the 
ligand directly, it was rather through subtle changes in the framework 
surrounding the binding sites (Zahnd et al., 2004). Moreover, the 
crystal structure of a Bapineuzumab Fab-Aβ peptide complex revealed 
that it captured Aβ in a monomeric helical conformation at the N-
terminus (Miles et al., 2013). Furthermore, the mobilization of toxic Aβ 
species from inert plaque material, might partially explain the failure 
of Bapineuzumab in clinical trials (Salloway et al., 2014). 
A recent study suggested that amino acids that interacted with 
Aβ in both the Solanezumab and Crenezumab antibodies had nearly 
the same sequence, suggesting they bind Aβ in the same way (Crespi 
et al., 2015), although reports had other suggested that they recognize 
















 Conformations Recognized Aria-E 
   
Monomer Oligomer Fibril 
 
Solanezumab* AA 16-26 Helix - β coil Yes Unknown Unknown Low 
Crenezumab* AA 16-26 Helix - β coil Yes Yes Yes Low 
Bapineuzumab* AA 1-7 Helix  Yes Unknown Yes High 
Gantenerumab* AA 1-11 Linear Unknown Yes Yes Low 
Aducanumab* AA 3-6 Linear No Unknown Yes High 
*Information retrieved from Alzforum.org 
 
Adolfsson and colleagues have reported that, unlike 
Solanezumab, Crenezumab binds aggregated forms of Aβ (Adolfsson et 
al., 2012). On the other hand, we have recently shown that, both 
antibodies showed a very similar staining profile in formalin-fixed and 
paraffin-embedded tissue and fresh frozen tissue and were able to 
detect plaques and CAA in humans in addition to plaques and 
intraneuronal Aβ in mice (Bouter et al., 2015). This goes to show the 
importance of structural studies of antibody-Aβ recognition, as IHC, 
though an important basis for diagnostic pathology, might not reflect 
antibody efficacy or action in vivo.   
Issues with antibody-target engagement in terms of affinity, 
species and conformation of Aβ bound may be dealt with before going 
to a clinical setting, with the help of information arising from the 












5. Summary & Conclusions 
 
The NT4X antibody has been raised against the human Aβ4-40 
peptide. We present here its characterization data as an antibody which 
recognizes both Aβ4-x and AβpE3-x N-truncated peptides in reducing and 
native conditions in PAGE where the NT4X is used as a primary 
antibody. Further analysis demonstrates that the phenylalanine at 
positon 4 of Aβ is essential for binding its target.  Having previously 
shown that the Aβ4-42 peptide is toxic in vitro and in vivo, we now 
demonstrate that the NT4X antibody is able to rescue the peptide’s 
toxicity.  
In this study, we have endeavored to present a new target for Aβ 
passive immunotherapy. In an AD mouse model, the Tg4-42, Aβ4-42 
expression leads to a progressive neuronal loss in the CA1 region. This is 
accompanied by a gradual loss of spatial reference memory from 
moderate (5 months) to severe at 6 months of age, in the homozygous 
line. This short timeframe allowed us to perform a preventative 
therapeutic passive immunization trials do commence before neuronal 
loss and reference memory deficits begin and to stop when they are 
severe. NT4X and its Fab fragment demonstrated a significant mitigation 
of neuron loss and rescue of spatial reference memory deficits in this 
treatment paradigm. In this regards, we also present neuronal loss in 
the Tg4-42 model as an alternative, more relevant, measurable clinical 
outcome. 
In light of failures in translation from pre-clinical studies to the 
clinic, our work has strived to present a wholesome picture of the 
therapeutic tool being used in complex to its target. We have been 
successful in co-crystallizing the NT4X Fab and the Aβ4-19 peptide. Our 
collaborators at the Macromolecular crystallography group (Max Planck 
for Biophysical Chemistry) are currently working on solving the crystal 
structure of the NT4X Fab:Aβ4-19 complex. Subsequent information may 
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be used to support the humanization process of the NT4X currently 
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Proteomics: 2D electrophoresis, protein purification and MALDI data acquisition,  
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Self-assessment  Understanding Speaking Writing 
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French  C1  Proficient user  C1  Proficient user  C1  Proficient user  C1 Proficient user  B2  Independent user  
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Artistic skills and hobbies Photography, Cooking, Hiking 
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 Conferences & Workshops:  
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